



(11)

**EP 1 239 869 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
**28.08.2013 Bulletin 2013/35**

(51) Int Cl.:  
**A61K 38/17** <sup>(2006.01)</sup> **A61K 39/395** <sup>(2006.01)</sup>  
**C07K 14/705** <sup>(2006.01)</sup> **C07K 16/28** <sup>(2006.01)</sup>  
**C12N 15/12** <sup>(2006.01)</sup> **A61P 35/00** <sup>(2006.01)</sup>

(21) Application number: **00990269.3**

(86) International application number:  
**PCT/US2000/034755**

(22) Date of filing: **19.12.2000**

(87) International publication number:  
**WO 2001/045730 (28.06.2001 Gazette 2001/26)**

(54) **TWEAK RECEPTOR**

TWEAK REZEPTOR

RECEPTEUR TWEAK

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**

(30) Priority: **20.12.1999 US 172878 P**  
**10.05.2000 US 203347 P**

(43) Date of publication of application:  
**18.09.2002 Bulletin 2002/38**

(60) Divisional application:  
**10181271.7 / 2 298 333**  
**10181389.7 / 2 298 334**

(73) Proprietor: **Immunex Corporation**  
**Thousand Oaks, CA 91320-1799 (US)**

(72) Inventor: **WILEY, Steven, R.**  
**Seattle, WA 98119 (US)**

(74) Representative: **Cornish, Kristina Victoria Joy et al**  
**Kilburn & Strode LLP**  
**20 Red Lion Street**  
**London**  
**WC1R 4PJ (GB)**

(56) References cited:  
**WO-A-00/42073 WO-A-94/10308**  
**WO-A-98/35061 WO-A-98/55508**  
**WO-A-99/61471 WO-A1-99/19490**  
**US-A- 5 759 546**

- **KAPLAU M J ET AL: "TH2 LYMPHOCYTES KIL.1 ANTIGEN PRESENTING MACROPHAGES THROUGH A TWEAK DEPENDENT PATHWAY" JOURNAL OF INVESTIGATIVE MEDICINE,US, AMERICAN FEDERATION FOR CLINICAL RESEARCH,, vol. 46, 1998, page 287A XP000907589 ISSN: 1081-5589**
- **MEIGHAN-MANTHA R L ET AL: "The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC, US, vol. 274, no. 46, 12 November 1999 (1999-11-12), pages 33166-33176, XP002191309, ISSN: 0021-9258, DOI: 10.1074/JBC.274.46.33166**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 239 869 B1**

**Description****FIELD OF THE INVENTION**

**[0001]** The present invention relates to the discovery of the functional receptor (TWEAKR) for the TWEAK protein. More particularly, the invention relates to the use of TWEAKR agonists and antagonists in methods of treatment, and to screening methods based on TWEAKR and the TWEAK-TWEAKR interaction.

**BACKGROUND OF THE INVENTION****A. Angiogenesis**

**[0002]** Angiogenesis is a multi-step developmental process that results in the formation of new blood vessels off of existing vessels. This spatially and temporally regulated process involves loosening of matrix contacts and support cell interactions in the existing vessels by proteases, followed by coordinated movement, morphological alteration, and proliferation of the smooth muscle and endothelial cells of the existing vessel. The nascent cells then extend into the target tissue followed by cell-cell interactions in which the endothelial cells form tubes which the smooth muscle cells surround. In a coordinated fashion, extracellular matrix proteins of the vessel are secreted and peri-endothelial support cells are recruited to support and maintain structural integrity (see, e.g., Daniel et al., Ann. Rev. Physiol. 2000(62):649, 2000). Angiogenesis plays important roles in both normal and pathological physiology.

**[0003]** Under normal physiological conditions, angiogenesis is involved in fetal and embryonic development, wound healing, organ regeneration, and female reproductive remodeling processes including formation of the endometrium, corpus luteum, and placenta. Angiogenesis is stringently regulated under normal conditions, especially in adult animals, and perturbation of the regulatory controls can lead to pathological angiogenesis.

**[0004]** Pathological angiogenesis has been implicated in the manifestation and/or progression of inflammatory diseases, certain eye disorders, and cancer. In particular, several lines of evidence support the concept that angiogenesis is essential for the growth and persistence of solid tumors and their metastases (see, e.g., Folkman, N. Engl. J. Med. 285:1182, 1971; Folkman et al., Nature 339:58, 1989; Kim et al., Nature 362:841, 1993; Hori et al., Cancer Res., 51: 6180, 1991). Angiogenesis inhibitors are therefore useful for the prevention (e.g., treatment of premalignant conditions), intervention (e.g., treatment of small tumors), and regression (e.g., treatment of large tumors) of cancers (see, e.g., Bergers et al., Science 284:808, 1999).

**[0005]** There is a need for additional compositions and methods of modulating angiogenesis for the prevention, abrogation, and mitigation of disease.

**B. TWEAK**

**[0006]** The TWEAK protein, which has also been called TREPA and Apo3L, is a member of the tumor necrosis factor (TNF) family and is expressed in a wide variety of human tissues (Chicheportiche et al., J. Biol. Chem., 272(51):32401, 1997; see also Wiley, PCT Publication No. WO 98/35061, 13 August 1998). Like most TNF family members, TWEAK is a Type II membrane protein with an extracellular C-terminal domain. Although TWEAK was originally described as a weak inducer of apoptosis, this induction of cell death was later shown to be indirect (Schneider et al., Eur. J. Immunol. 29:1785, 1999).

**[0007]** Lynch et al. demonstrated that TWEAK directly induces endothelial cell proliferation and angiogenesis (J. Biol. Chem., 274(13):8455, 1999). Picomolar concentrations of recombinant soluble TWEAK induce proliferation in multiple endothelial cell lines and in aortic smooth muscle cells, and reduce the requirement for serum and growth factors in culture. Moreover, TWEAK induces a strong angiogenic response in a rat corneal pocket assay. Since TNF family members initiate biological responses by signaling through members of the TNF receptor family, there has been great interest in identifying and characterizing the TWEAK receptor.

**[0008]** Marsters et al. reported that TWEAK binds to and signals through a death-domain containing receptor known variously as DR3, Apo3, WSL-1, TRAMP, or LARD (Marsters et al., Current Biology 8(9):525, 1998). Schneider et al., however, showed that TWEAK binds to and signals in Kym-1 cells but that Kym-1 cells do not express the receptor DR3 (Schneider et al., Eur. J. Immunol. 29:1785, 1999). These results suggest the existence of a yet to be identified TWEAK receptor.

**[0009]** Because TWEAK induces angiogenesis in vivo, there is a particular need to identify the major functional TWEAK receptor. Once identified, the TWEAK receptor may be used to screen for and develop TWEAK receptor agonists and antagonists for the modulation of angiogenesis and the treatment of human disease.

**[0010]** WO 98/35061 discloses the use of TWEAK as a therapeutic agent to promote vascularization and wound healing and discloses strategies using antisense RNA or blocking antibodies against TWEAK to prevent solid tumor

vascularization. WO 00/42073 discloses reagents which modify the activity of TWEAK for the treatment of immunological disorders.

**[0011]** Meighan-Mantha et al., J. Biol. Chem. 274 (46), 33166-33176 (1999) reported Fn14 (TWEAKR) expression in various mouse tissues.

## **SUMMARY OF THE INVENTION**

**[0012]** The present invention is based upon the identification and biological characterization of the major functional TWEAK receptor. As described below, cDNA encoding the TWEAK receptor was molecularly cloned from a human endothelial cell expression library.

**[0013]** Although DNA and deduced amino acid sequences corresponding to the TWEAK receptor identified herein have been reported (see, e.g., Kato et al., PCT Publication No. WO 98/55508; 10 December 1998 and Incyte, PCT Publication No. WO 99/61471, 02 December 1999), it was not heretofore appreciated that these sequences encode a receptor for TWEAK or that the encoded polypeptide is involved in modulating angiogenesis. Similarly, investigators have recently claimed methods of making and using TWEAK receptor antagonists to treat immunological disorders, but without identifying the major TWEAK receptor or its role in angiogenesis (Rennert, PCT Publication No. WO 00/42073, 20 July 2000). These deficiencies have been addressed, as described herein, by identification of the major TWEAK receptor (TWEAKR) and characterization of its biological activities. The identification of TWEAKR has led to the development of compositions for the modulation of angiogenesis, and also provides screening tools for the identification of diagnostics and therapeutics.

**[0014]** The present invention provides the use of an isolated polypeptide comprising a soluble fragment of the TWEAK receptor extracellular domain that has the ability to bind TWEAK in the manufacture of a medicament for use in inhibiting angiogenesis in a mammal, wherein the TWEAK receptor extracellular domain consists of the sequence as set out in residues 28 to 79 of SEQ ID NO: 7.

**[0015]** The invention also provides the use of an antibody that specifically binds to the TWEAK receptor extracellular domain in the manufacture of a medicament for use in modulating angiogenesis (such as promoting or inhibiting angiogenesis) in a mammal, wherein the TWEAK receptor extracellular domain consists of the sequence as set out in residues 28 to 79 of SEQ ID NO: 7.

**[0016]** The mammal may be a human, and the polypeptide may comprise an Fc polypeptide or leucine zipper domain. The antibody may be selected from the group consisting of monoclonal antibodies, humanised antibodies, transgenic antibodies and human antibodies. The antibody may be conjugated to a radioisotope, to a plant-, fungus-, or bacterial-derived toxin such as ricin A or diphtheria toxin, or to another chemical poison.

**[0017]** The polypeptide or the antibody may disrupt the interaction between the TWEAK receptor and a TRAF molecule.

**[0018]** The mammal may also be treated with a chemotherapeutic agent, and the chemotherapeutic agent may be selected from the group consisting of alkylating agents, antimetabolites, vinca alkaloids and other plant-derived chemotherapeutics, nitrosoureas, antitumour antibiotics, antitumour enzymes, topoisomerase inhibitors, platinum analogs, adrenocortical suppressants, hormones, hormone agonists, hormone antagonists, antibodies, immunotherapeutics, blood cell factors, radiotherapeutics and biological response modifiers, or the chemotherapeutic agent may be selected from the group consisting of cisplatin, cyclophosphamide, mechlorethamine, melphalan, bleomycin, carboplatin, fluorouracil, 5-fluorodeoxyuridine, methotrexate, taxol, asparaginase, vincristine, and vinblastine, lymphokines and cytokines such as interleukins, interferons (including alpha, beta, or delta), and TNF, chlorambucil, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, cytarabine, mercaptopurine, thioguanine, vindesine, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin, L-asparaginase, hydroxyurea, methylhydrazine, mitotane, tamoxifen, and fluoxymesterone, or the chemotherapeutic agent may be selected from the group consisting of Flt3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-1BB ligand, anti-4-1BB antibodies, TNF antagonists and TNF receptor antagonists, TRAIL, CD 148 agonists, VEGF antagonists, VEGF receptor antagonists, and Tek antagonists.

**[0019]** The use of an antibody according to the invention may be for treating a vascularization deficiency in cardiac or peripheral tissue, including coronary artery disease, myocardial ischemia, myocardial infarction, angina pectoris, peripheral circulation deficits, limb ischemia/reperfusion injury; enhancing wound healing, organ transplantation, reconnection of severed digits or limbs, or vascular or skin grafting; or use in conjunction with bypass surgery or angioplasty.

**[0020]** The invention also provides a TWEAKR antagonist comprising an isolated polypeptide comprising a soluble fragment of a TWEAK receptor extracellular domain that has the ability to bind to TWEAK for use in medicine, wherein the TWEAK receptor extracellular domain consists of the sequence as set out in residues 28 to 79 of SEQ ID NO: 7

**[0021]** Also provided by the invention is a method of identifying a compound that is capable of modulating angiogenesis, the method comprising identifying a test compound that binds to a TWEAK receptor extracellular domain, wherein the test compound is not TWEAK, and wherein the TWEAK receptor extracellular domain consists of the sequence as set out in residues 28 to 79 of SEQ ID NO:7, the method may comprise identifying a test compound that affects the interaction between TWEAK and a TWEAK receptor extracellular domain, wherein the TWEAK receptor extracellular domain con-

sists of the sequence as set out in residues 28 to 79 of SEQ ID NO: 7. The invention also provides a method of identifying a compound that is capable of modulating angiogenesis, the method comprising identifying a test compound that modulates angiogenesis by modulating the interaction, between a TWEAK receptor and TRAF, wherein the TWEAK receptor comprises an extracellular domain consisting of the sequence set out in residues 28 to 79 of SEQ ID NO:7. The methods of the invention may also comprise determining the ability of the test compound to modulate endothelial cell proliferation and/or endothelial cell migration and/or angiogenesis; the modulation may be stimulating or inhibitory.

## **BRIEF DESCRIPTION OF THE DRAWINGS**

**[0022]**

Figure 1 shows a sequence alignment of the human and murine TWEAK receptor polypeptide sequences. The top sequence is the murine TWEAK receptor polypeptide (SEQ ID NO:5), and the bottom sequence is the human TWEAK receptor polypeptide (SEQ ID NO:4).

Figure 2 shows the effect of TWEAKR-Fc on PMA-induced HRMEC wound closure.

Figure 3 shows the effect of TWEAKR-Fc on EGF-induced HRMEC wound closure.

Figure 4 shows the effect of human TWEAKR-Fc on TWEAK-induced (100 ng/ml) HUVEC proliferation.

Figure 5 shows the effect of human TWEAKR-Fc on FGF-2-induced (10 ng/ml) HUVEC proliferation.

## **DETAILED DESCRIPTION OF THE INVENTION**

**[0023]** The present invention is directed to the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. The invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis.

### **A. Abbreviations and Terminology Used in the Specification**

**[0024]** "4-1BB" and "4-1BB ligand" (4-1BB-L) are polypeptides described, inter alia, in U.S. Patent No. 5,674,704, including soluble forms thereof.

**[0025]** "bFGF" is basic fibroblast growth factor.

**[0026]** "BSA" is bovine serum albumin.

**[0027]** "CD40 ligand" (CD40L) is a polypeptide described, inter alia, in U.S. Patent No. 5,716,805, including soluble forms thereof.

**[0028]** "CHO" is a Chinese hamster ovary cell line.

**[0029]** "DMEM" is Dulbecco's Modified eagle Medium, a commercially available cell culture medium.

**[0030]** "ELISA" is Enzyme-Linked Immunosorbent Assay.

**[0031]** "Flt3L" is Flt3 ligand, a polypeptide described, inter alia, in U.S. Patent No. 5,554,512, including soluble forms thereof.

**[0032]** "HRMEC" are primary human renal microvascular endothelial cells.

**[0033]** "HUVEC" is a line of human umbilical vein endothelial cells.

**[0034]** "PBS" is phosphate buffered saline.

**[0035]** "PMA" is phorbol 12-myristate-13-acetate.

**[0036]** "RTKs" are receptor tyrosine kinases.

**[0037]** "Tek," which has also been called Tie2 and ork, is an RTK that is predominantly expressed in vascular endothelium. The molecular cloning of human Tek (ork) has been described by Ziegler, U.S. Patent No. 5,447,860. "Tek antagonists" are described, inter alia, in Cerretti et al., PCT Publication No. WO 00/75323, 14 December 2000.

**[0038]** "TNFR" is a tumor necrosis factor receptor, including soluble forms thereof. "TNFR/Fc" is a tumor necrosis factor receptor-Fc fusion polypeptide.

**[0039]** "TRAIL" is TNF-related apoptosis-inducing ligand, a type II transmembrane polypeptide in the TNF family described, inter alia, in U.S. Patent No. 5,763,223, including soluble forms thereof.

**[0040]** "VEGF" is vascular endothelial growth factor, also known as VPF or vascular permeability factor.

### **B. Soluble TWEAK Receptor Polypeptides**

**[0041]** As described in the examples below, the native human TWEAK receptor cDNA has the sequence SEQ ID NO: 3, which encodes a 129 residue polypeptide (SEQ ID NO:4). Examination of the DNA sequence predicts a polypeptide having an approximately 78 amino acid extracellular domain (residues 1-78 of SEQ ID NO:4, including the signal peptide), an approximately 23 amino acid transmembrane domain (residues 79-101 of SEQ ID NO:4), and an approximately 28

amino acid intracellular domain (residues 102-129 of SEQ ID NO:4). The TWEAK receptor sequence has also been reported by Kato et al., PCT Publication No. WO 98/55508, 10 December 1998 and by Incyte, PCT Publication No. WO 99/61471, 02 December 1999. As used herein, "TWEAKR" includes polypeptides having these sequences, and in particular comprising amino acids 28-79 of SEQ ID NO:7, as well as naturally occurring variants thereof.

**[0042]** In one aspect of the invention, a soluble TWEAK receptor fragment is used as a TWEAKR antagonist to inhibit angiogenesis and/or to inhibit the binding of TWEAK ligand to TWEAKR.

**[0043]** Soluble polypeptides are capable of being secreted from the cells in which they are expressed. The use of soluble forms of polypeptides is advantageous for certain applications. Purification of the polypeptides from recombinant host cells is facilitated since the polypeptides are secreted, and soluble proteins are generally suited for parenteral administration. A secreted soluble polypeptide may be identified (and distinguished from its non-soluble membrane-bound counterparts) by separating intact cells which express the desired polypeptide from the culture medium, e.g., by centrifugation, and assaying the medium (supernatant) for the presence of the desired polypeptide. The presence of the desired polypeptide in the medium indicates that the polypeptide was secreted from the cells and thus is a soluble form of the polypeptide. Soluble polypeptides may be prepared by any of a number of conventional techniques. A DNA sequence encoding a desired soluble polypeptide may be subcloned into an expression vector for production of the polypeptide, or the desired encoding DNA fragment may be chemically synthesized.

**[0044]** Soluble TWEAKR polypeptides comprise all or part of the TWEAKR extracellular domain, but generally lack the transmembrane domain that would cause retention of the polypeptide at the cell surface. Soluble polypeptides may include part of the transmembrane domain or all or part of the cytoplasmic domain as long as the polypeptide is secreted from the cell in which it is produced. Soluble TWEAKR polypeptides advantageously comprise a native or heterologous signal peptide when initially synthesized, to promote secretion from the cell, but the signal sequence is cleaved upon secretion. The term "TWEAKR extracellular domain" is intended to encompass all or part of the native TWEAKR extracellular domain, as well as related forms including but not limited to: (a) fragments, (b) variants, (c) derivatives, and (d) fusion polypeptides. The ability of these related forms to inhibit angiogenesis or other TWEAKR-mediated responses may be determined in vitro or in vivo, using methods such as those exemplified below or using other assays known in the art. Examples of soluble TWEAKR polypeptides are provided below.

**[0045]** A multimeric form of a soluble TWEAKR polypeptide ("soluble TWEAKR multimer") may be used as an antagonist to block the binding of TWEAK to TWEAKR, to inhibit angiogenesis or other TWEAKR-mediated responses.

**[0046]** Soluble TWEAKR multimers are covalently-linked or non-covalently-linked multimers, including dimers, trimers, or higher multimers. Multimers may be linked by disulfide bonds formed between cysteine residues on different soluble TWEAKR polypeptides. Herein described are multimers comprising multiple soluble TWEAKR polypeptides joined via covalent or non-covalent interactions between peptide moieties fused to the soluble TWEAKR polypeptides. Such peptides may be peptide linkers (spacers), or peptides that have the property of promoting multimerization. Leucine zippers and certain polypeptides derived from antibodies are among the peptides that can promote multimerization of soluble TWEAKR polypeptides attached thereto, as described in more detail below.

**[0047]** The multimers may comprise from two to four soluble TWEAKR polypeptides.

**[0048]** A soluble TWEAKR multimer may be prepared using polypeptides derived from immunoglobulins. Preparation of fusion proteins comprising certain heterologous polypeptides fused to various portions of antibody-derived polypeptides (including the Fc domain) has been described, e.g., by Ashkenazi et al. (Proc. Natl. Acad. Sci. USA 88:10535, 1991); Byrn et al. (Nature 344:677, 1990); and Hollenbaugh and Aruffo ("Construction of Immunoglobulin Fusion Proteins", in Current Protocols in Immunology, Suppl. 4, pages 10.19.1-10.19.11, 1992).

**[0049]** One embodiment of the present invention is directed to a TWEAKR-Fc dimer comprising two fusion proteins created by fusing soluble TWEAKR to an Fc polypeptide. A gene fusion encoding the TWEAKR-Fc fusion protein is inserted into an appropriate expression vector. TWEAKR-Fc fusion proteins are expressed in host cells transformed with the recombinant expression vector, and allowed to assemble much like antibody molecules, whereupon interchain disulfide bonds form between the Fc moieties to yield divalent soluble TWEAKR. The term "Fc polypeptide" as used herein includes native and mutein forms of polypeptides derived from the Fc region of an antibody. Truncated forms of such polypeptides containing the hinge region that promotes dimerization are also included.

**[0050]** One suitable Fc polypeptide, described in PCT application WO 93/10151, is a single chain polypeptide extending from the N-terminal hinge region to the native C-terminus of the Fc region of a human IgG1 antibody. Another useful Fc polypeptide is the Fc mutein described in U.S. Patent 5,457,035 and by Baum et al., EMBO J. 13:3992, 1994. The amino acid sequence of this mutein is identical to that of the native Fc sequence presented in WO 93/10151, except that amino acid 19 has been changed from Leu to Ala, amino acid 20 has been changed from Leu to Glu, and amino acid 22 has been changed from Gly to Ala. The mutein exhibits reduced affinity for Fc receptors. Fusion polypeptides comprising Fc moieties, and multimers formed therefrom, offer an advantage of facile purification by affinity chromatography over Protein A or Protein G columns, and Fc fusion polypeptides may provide a longer in vivo half life, which is useful in therapeutic applications, than unmodified polypeptides.

**[0051]** A soluble TWEAKR polypeptide may be substituted for the variable portion of an antibody heavy or light chain.

If fusion proteins are made with both heavy and light chains of an antibody, it is possible to form a soluble TWEAKR multimer with as many as four soluble TWEAKR polypeptides.

**[0052]** Alternatively, the soluble TWEAKR multimer is a fusion protein comprising multiple soluble TWEAKR polypeptides, with or without peptide linkers (spacers), or peptides that have the property of promoting multimerization. Among the suitable peptide linkers are those described in U.S. Patents 4,751,180, 4,935,233, and 5,073,627. A DNA sequence encoding a desired peptide linker may be inserted between, and in the same reading frame as, the DNA sequences encoding TWEAKR, using conventional techniques known in the art. For example, a chemically synthesized oligonucleotide encoding the linker may be ligated between sequences encoding soluble TWEAKR. In particular embodiments, a fusion protein comprises from two to four soluble TWEAKR polypeptides, separated by peptide linkers.

**[0053]** Another method for preparing soluble TWEAKR multimers involves use of a leucine zipper domain. Leucine zipper domains are peptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., *Science* 240:1759, 1988), and have since been found in a variety of different proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins are described in PCT application WO 94/10308, and the leucine zipper derived from lung surfactant protein D (SPD) described in Hoppe et al. *FEBS Lett.* 344:191, 1994. The use of a modified leucine zipper that allows for stable trimerization of a heterologous protein fused thereto is described in Fanslow et al., *Semin. Immunol.* 6:267, 1994. Recombinant fusion proteins comprising a soluble TWEAKR polypeptide fused to a leucine zipper peptide are expressed in suitable host cells, and the soluble TWEAKR multimer that forms is recovered from the culture supernatant.

**[0054]** For some applications, the soluble TWEAKR multimers of the present invention are believed to provide certain advantages over the use of monomeric forms. Fc fusion polypeptides, for example, typically exhibit an increased in vivo half life as compared to an unmodified polypeptide.

**[0055]** The present invention encompasses the use of various forms of soluble TWEAKR multimers that retain the ability to inhibit angiogenesis or other TWEAKR-mediated responses. The term "soluble TWEAKR multimer" is intended to encompass multimers containing all or part of the native TWEAKR extracellular domain, as well as related forms including, but not limited to, multimers of: (a) fragments, (b) variants, (c) derivatives, and (d) fusion polypeptides of soluble TWEAKR. The ability of these related forms to inhibit angiogenesis or other TWEAKR-mediated responses may be determined in vitro or in vivo, using methods such as those exemplified in the examples or using other assays known in the art.

**[0056]** Among the soluble TWEAKR polypeptides and soluble TWEAKR multimers useful in practicing the present invention are TWEAKR variants that retain the ability to bind ligand and/or inhibit angiogenesis or other TWEAKR-mediated responses. Such TWEAKR variants include polypeptides that are substantially homologous to native TWEAKR, but which have an amino acid sequence different from that of a native TWEAKR because of one or more deletions, insertions or substitutions.

**[0057]** TWEAKR polypeptides may comprise from one to ten deletions, insertions or substitutions of amino acid residues, when compared to a native TWEAKR sequence. Included as variants of TWEAKR polypeptides are those variants that are naturally occurring, such as allelic forms and alternatively spliced forms, as well as variants that have been constructed by modifying the amino acid sequence of a TWEAKR polypeptide or the nucleotide sequence of a nucleic acid encoding a TWEAKR polypeptide.

**[0058]** Generally, substitutions for one or more amino acids present in the native polypeptide should be made conservatively. Examples of conservative substitutions include substitution of amino acids outside of the active domain(s), and substitution of amino acids that do not alter the secondary and/or tertiary structure of TWEAKR. Additional examples include substituting one aliphatic residue for another, such as Ile, Val, Leu, or Ala for one another, or substitutions of one polar residue for another, such as between Lys and Arg; Glu and Asp; or Gln and Asn, or substitutions of one aromatic residue for another, such as Phe, Trp, or Tyr for one another. Other such conservative substitutions, for example, substitutions of entire regions having similar hydrophobicity characteristics, are known in the art.

**[0059]** The TWEAKR variant may be at least about 70% identical in amino acid sequence to the amino acid sequence of native TWEAKR; the TWEAKR variant may be at least about 80% identical in amino acid sequence to the amino acid sequence of native TWEAKR. The TWEAKR variant may be at least 90% identical in amino acid sequence to the amino acid sequence of native TWEAKR; the TWEAKR variant may be at least about 95% identical in amino acid sequence to the amino acid sequence of native TWEAKR. The TWEAKR variant may be at least 98% identical in amino acid sequence to the amino acid sequence of native TWEAKR; the TWEAKR variant may be at least 99% identical in amino acid sequence to the amino acid sequence of native TWEAKR. Percent identity, in the case of both polypeptides and nucleic acids, may be determined by visual inspection. Percent identity may also be determined using the alignment method of Needleman and Wunsch (*J. Mol. Biol.* 48:443, 1970) as revised by Smith and Waterman (*Adv. Appl. Math.* 2: 482, 1981). Preferably, percent identity is determined by using a computer program for example, the GAP computer program version 10.x available from the Genetics Computer Group (GCG; Madison, WI, see also Devereux et al., *Nucl. Acids Res.* 12:387, 1984). The preferred default parameters for the GAP program include: (1) a unary comparison matrix

(containing a value of 1 for identities and 0 for non-identities) for nucleotides, and the weighted comparison matrix of Gribskov and Burgess, Nucl. Acids Res. 14:6745, 1986, as described by Schwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358, 1979 for amino acids; (2) a penalty of 30 (amino acids) or 50 (nucleotides) for each gap and an additional 1 (amino acids) or 3 (nucleotides) penalty for each symbol in each gap; (3) no penalty for end gaps; and (4) no maximum penalty for long gaps. Other programs used by one skilled in the art of sequence comparison may also be used. For fragments of TWEAKR, the percent identity is calculated based on that portion of TWEAKR that is present in the fragment.

**[0060]** The present invention further encompasses the use of soluble TWEAKR polypeptides with or without associated native-pattern glycosylation. TWEAKR expressed in yeast or mammalian expression systems (e.g., COS-1 or COS-7 cells) may be similar to or significantly different from a native TWEAKR polypeptide in molecular weight and glycosylation pattern, depending upon the choice of expression system. Expression of TWEAKR polypeptides in bacterial expression systems, such as *E. coli*, provides non-glycosylated molecules. Different host cells may also process polypeptides differentially, resulting in heterogeneous mixtures of polypeptides with variable N- or C-termini.

**[0061]** The primary amino acid structure of soluble TWEAKR polypeptides may be modified to create derivatives by forming covalent or aggregative conjugates with other chemical moieties, such as glycosyl groups, lipids, phosphate, acetyl groups and the like. Covalent derivatives of TWEAKR may be prepared by linking particular functional groups to TWEAKR amino acid side chains or at the N-terminus or C-terminus of a TWEAKR polypeptide.

**[0062]** Fusion polypeptides of soluble TWEAKR that are useful in practicing the invention also include covalent or aggregative conjugates of a TWEAKR polypeptide with other polypeptides added to provide novel polyfunctional entities.

### C. TWEAK Receptor Antibodies

**[0063]** Herein described are antigenic epitopes of the TWEAKR extracellular domain. Such epitopes are useful for raising antibodies, and in particular the blocking monoclonal antibodies described in more detail below. Such epitopes or variants thereof can be produced using techniques well known in the art such as solid-phase synthesis, chemical or enzymatic cleavage of a polypeptide, or using recombinant DNA technology.

**[0064]** The claimed invention encompasses compositions and uses of antibodies that are immunoreactive with TWEAKR polypeptides. Such antibodies "bind specifically" to TWEAKR polypeptides, meaning that they bind via antigen-binding sites of the antibody as compared to non-specific binding interactions. The terms "antibody" and "antibodies" are used herein in their broadest sense, and include, without limitation, intact monoclonal and polyclonal antibodies as well as fragments such as Fv, Fab, and F(ab')<sub>2</sub> fragments, single-chain antibodies such as scFv, and various chain combinations. The antibodies of the present invention are preferably humanized, and more preferably human. The antibodies may be prepared using a variety of well-known methods including, without limitation, immunization of animals having native or transgenic immune repertoires, phage display, hybridoma and recombinant cell culture, and transgenic plant and animal bioreactors.

**[0065]** Both polyclonal and monoclonal antibodies may be prepared by conventional techniques. See, for example, Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kennet et al. (eds.), Plenum Press, New York (1980); and Antibodies: A Laboratory Manual, Harlow and Land (eds.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1988).

**[0066]** Hybridoma cell lines that produce monoclonal antibodies specific for the polypeptides of the invention are also contemplated herein. Such hybridomas may be produced and identified by conventional techniques. One method for producing such a hybridoma cell line comprises immunizing an animal with a polypeptide, harvesting spleen cells from the immunized animal, fusing said spleen cells to a myeloma cell line, thereby generating hybridoma cells, and identifying a hybridoma cell line that produces a monoclonal antibody that binds the polypeptide. The monoclonal antibodies produced by hybridomas may be recovered by conventional techniques.

**[0067]** The monoclonal antibodies of the present invention include chimeric antibodies, e.g., "humanized" versions of antibodies originally produced in mice or other non-human species. A humanized antibody is an engineered antibody that typically comprises the variable region of a non-human (e.g., murine) antibody, or at least complementarity determining regions (CDRs) thereof, and the remaining immunoglobulin portions derived from a human antibody. Procedures for the production of chimeric and further engineered monoclonal antibodies include those described in Riechmann et al. (Nature 332:323, 1988), Liu et al. (PNAS 84:3439, 1987), Larrick et al. (Bio/Technology 7:934, 1989), and Winter and Harris (TIPS 14:139, May, 1993). Such humanized antibodies may be prepared by known techniques and offer the advantage of reduced immunogenicity when the antibodies are administered to humans.

**[0068]** Procedures that have been developed for generating human antibodies in non-human animals may be employed in producing antibodies. The antibodies may be partially human or preferably completely human. For example, transgenic mice into which genetic material encoding one or more human immunoglobulin chains has been introduced may be employed. Such mice may be genetically altered in a variety of ways. The genetic manipulation may result in human immunoglobulin polypeptide chains replacing endogenous immunoglobulin chains in at least some, and preferably vir-

tually all, antibodies produced by the animal upon immunization.

**[0069]** Mice in which one or more endogenous immunoglobulin genes have been inactivated by various means have been prepared. Human immunoglobulin genes have been introduced into the mice to replace the inactivated mouse genes. Antibodies produced in the animals incorporate human immunoglobulin polypeptide chains encoded by the human genetic material introduced into the animal. Examples of techniques for the production and use of such transgenic animals to make antibodies (which are sometimes called "transgenic antibodies") are described in U.S. Patent Nos. 5,814,318, 5,569,825, and 5,545,806.

#### D. Inhibitory Antisense, Ribozyme, and Triple Helix Approaches

**[0070]** Modulation of angiogenesis in a tissue or group of cells may also be ameliorated by decreasing the level of TWEAKR gene expression and/or TWEAK receptor-ligand interaction by using TWEAK receptor or ligand gene sequences in conjunction with well-known antisense, gene "knock-out," ribozyme and/or triple helix methods to decrease the level of TWEAK receptor or ligand gene expression. Among the compounds that may exhibit the ability to modulate the activity, expression or synthesis of the TWEAK receptor or ligand gene, including the ability to modulate angiogenesis, are antisense, ribozyme, and triple helix molecules. Such molecules may be designed to reduce or inhibit either unimpaired, or if appropriate, mutant target gene activity. Techniques for the production and use of such molecules are well known to those of skill in the art.

#### E. Recombinant Production of TWEAK Receptor Polypeptides

**[0071]** TWEAK polypeptides, including soluble TWEAKR polypeptides, fragments, and fusion polypeptides, used in the present invention may be prepared using a recombinant expression system. Host cells transformed with a recombinant expression vector ("recombinant host cells") encoding the TWEAKR polypeptide are cultured under conditions that promote expression of TWEAKR and the TWEAKR is recovered. TWEAKR polypeptides can also be produced in transgenic plants or animals, or by chemical synthesis.

**[0072]** Herein described are nucleic acid molecules encoding the TWEAKR polypeptides used in the invention, including: (a) nucleic acids that encode residues 28-79 of SEQ ID NO:7 and fragments thereof that bind TWEAK; (b) nucleic acids that are at least 70%, 80%, 90%, 95%, 98%, or 99% identical to a nucleic acid of (a), and which encode a polypeptide capable of binding TWEAK; and (c) nucleic acids that hybridize at moderate stringency to a nucleic acid of (a), and which encode a polypeptide capable of binding TWEAK.

**[0073]** Due to degeneracy of the genetic code, there can be considerable variation in nucleotide sequences encoding the same amino acid sequence. Nucleic acid sequences capable of hybridizing under moderately stringent conditions (e.g., prewashing solution of 5 X SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0) and hybridization conditions of 50°C, 5 X SSC, overnight) to the DNA sequences encoding TWEAKR are described. The skilled artisan can determine additional combinations of salt and temperature that constitute moderate hybridization stringency (see also, Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989; Maniatis, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1982; and Ausubel, Current Protocols in Molecular Biology, Wiley and Sons, 1989 and later versions). Conditions of higher stringency include higher temperatures for hybridization and post-hybridization washes, and/or lower salt concentration. Percent identity of nucleic acids may be determined using the methods described above for polypeptides, i.e., by methods including visual inspection and the use of computer programs such as GAP.

**[0074]** Any suitable expression system may be employed for the production of recombinant TWEAKR. Recombinant expression vectors include DNA encoding a TWEAKR polypeptide operably linked to suitable transcriptional and translational regulatory nucleotide sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the TWEAKR DNA sequence. Thus, a promoter nucleotide sequence is operably linked to a TWEAKR DNA sequence if the promoter nucleotide sequence controls the transcription of the TWEAKR DNA sequence. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, an mRNA ribosomal binding site, and appropriate sequences which control transcription and translation initiation and termination. A sequence encoding an appropriate signal peptide (native or heterologous) can be incorporated into expression vectors. A DNA sequence for a signal peptide (referred to by a variety of names including secretory leader, leader peptide, or leader) may be fused in frame to the TWEAKR sequence so that the TWEAKR polypeptide is initially translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cells promotes extracellular secretion of the TWEAKR polypeptide. The signal peptide is cleaved from the TWEAKR polypeptide upon secretion of TWEAKR from the cell.

**[0075]** Suitable host cells for expression of TWEAKR polypeptides include prokaryotes, yeast and higher eukaryotic cells, including insect and mammalian cells. Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, insect, and mammalian cellular hosts are described, for example, in Pouwels et al. Cloning Vectors: A Laboratory



Manual, Elsevier, New York. 1985.

**[0076]** Prokaryotes include gram negative or gram positive organisms, for example. *E. coli* or *Bacilli*. Suitable prokaryotic host cells for transformation include, for example. *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium*, and various other species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*. In a prokaryotic host cell, such as

*E. coli*, TWEAKR polypeptides may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in the prokaryotic host cell. The N-terminal Met may be cleaved from the expressed recombinant polypeptide. **[0077]** Expression vectors for use in prokaryotic host cells generally comprise one or more phenotypic selectable marker gene(s). A phenotypic selectable marker gene is, for example, a gene encoding a protein that confers antibiotic resistance or that supplies an autotrophic requirement. Examples of useful expression vectors for prokaryotic host cells include those derived from commercially available plasmids such as the cloning vector pBR322 (ATCC 37017), pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells. An appropriate promoter and a TWEAKR DNA sequence are inserted into the pBR322 vector. Other commercially available vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, WI, USA).

**[0078]** Promoter sequences commonly used for recombinant prokaryotic host cell expression vectors include  $\beta$ -lactamase (penicillinase), lactose promoter system (Chang et al., Nature 275:615, 1978; Goeddel et al., Nature 281:544, 1979), tryptophan (trp) promoter system (Goeddel et al., Nucl. Acids Res. 8:4057, 1980; EP-A-36776) and tac promoter (Maniatis, Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, p. 412, 1982). A particularly useful prokaryotic host cell expression system employs a phage  $\lambda$   $P_L$  promoter and a cl857ts thermolabile repressor sequence. Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the  $\lambda$   $P_L$  promoter include plasmid pHUB2 (resident in *E. coli* strain JMB9, ATCC 37092) and pPLc28 (resident in *E. coli* RR1, ATCC 53082).

**[0079]** TWEAKR polypeptides may also be expressed in yeast host cells, preferably from the *Saccharomyces* genus (e.g., *S. cerevisiae*). Other genera of yeast, such as *Pichia* or *Kluyveromyces*, may also be employed. Yeast vectors will often contain an origin of replication sequence from a  $2\mu$  yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Suitable promoter sequences for yeast vectors include, among others, promoters for metallothionein. 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem. 255:2073, 1980) or other glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg. 7:149, 1968; Holland et al., Biochem. 17:4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase. 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phospho-glucose isomerase, and glucokinase. Other suitable vectors and promoters for use in yeast expression are further described in Hitzeman, EP-73,657. Another alternative is the glucose-repressible ADH2 promoter described by Russell et al. (J. Biol. Chem. 258:2674, 1982) and Beier et al. (Nature 300:724, 1982). Shuttle vectors replicable in both yeast and *E. coli* may be constructed by inserting DNA sequences from pBR322 for selection and replication in *E. coli* (Amp<sup>r</sup> gene and origin of replication) into the above-described yeast vectors.

**[0080]** The yeast  $\alpha$ -factor leader sequence may be employed to direct secretion of recombinant polypeptides. The  $\alpha$ -factor leader sequence is often inserted between the promoter sequence and the structural gene sequence. See, e.g., Kurjan et al., Cell 30:933, 1982; Bitter et al., Proc. Natl. Acad. Sci. USA 81:5330, 1984. Other leader sequences suitable for facilitating secretion of recombinant polypeptides from yeast hosts are known to those of skill in the art. A leader sequence may be modified near its 3' end to contain one or more restriction sites. This will facilitate fusion of the leader sequence to the structural gene.

**[0081]** Yeast transformation protocols are known to those of skill in the art. One such protocol is described by Hinnen et al., Proc. Natl. Acad. Sci. USA 75:1929, 1978. The Hinnen et al. protocol selects for Trp<sup>+</sup> transformants in a selective medium, wherein the selective medium consists of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10  $\mu$ g/ml adenine and 20  $\mu$ g/ml uracil.

**[0082]** Yeast host cells transformed by vectors containing an ADH2 promoter sequence may be grown for inducing expression in a "rich" medium. An example of a rich medium is one consisting of 1% yeast extract, 2% peptone, and 1% glucose supplemented with 80  $\mu$ g/ml adenine and 80  $\mu$ g/ml uracil. Derepression of the ADH2 promoter occurs when glucose is exhausted from the medium.

**[0083]** Insect host cell culture systems also may be employed to express recombinant TWEAKR polypeptides, including soluble TWEAKR polypeptides. Baculovirus systems for production of heterologous polypeptides in insect cells are reviewed by Luckow and Summers, Bio/Technology 6:47, 1988.

**[0084]** Mammalian cells are particularly preferred for use as host cells. Examples of suitable mammalian host cell lines include the COS-7 line of monkey kidney cells (ATCC CRL 1651) (Gluzman et al., Cell 23:175, 1981), L cells, C127 cells, 3T3 cells, (ATCC CCL 163), Chinese hamster ovary (CHO) cells, HeLa cells, and BHK (ATCC CRL 10) cell lines, and the CV1/EBNA cell line derived from the African green monkey kidney cell line CV1 (ATCC CCL 70) as described by McMahan et al. (EMBO J. 10:2821, 1991). For the production of therapeutic polypeptides it is particularly advantageous to use a mammalian host cell line which has been adapted to grow in media that does not contain animal proteins.

**[0085]** Established methods for introducing DNA into mammalian cells have been described (Kaufman, R.J., Large Scale Mammalian Cell Culture, 1990, pp. 15-69). Additional protocols using commercially available reagents, such as Lipofectamine (Gibco/BRL) or Lipofectamine-Plus, can be used to transfect cells (Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413, 1987). In addition, electroporation can be used to transfect mammalian cells using conventional procedures, such as those in Sambrook et al. Molecular Cloning: A Laboratory Manual, 2 ed. Vol. 1-3. Cold Spring Harbor Laboratory Press, 1989). Selection of stable transformants can be performed using methods known in the art, such as, for example, resistance to cytotoxic drugs. Kaufman et al., Meth. in Enzymology 185:487, 1990, describes several selection schemes, such as dihydrofolate reductase (DHFR) resistance. A suitable host strain for DHFR selection can be CHO strain DX-B11, which is deficient in DHFR (Urlaub and Chasin, Proc. Natl. Acad. Sci. USA 77:4216, 1980). A plasmid expressing the DHFR cDNA can be introduced into strain DX-B11, and only cells that contain the plasmid can grow in the appropriate selective media. Other examples of selectable markers that can be incorporated into an expression vector include cDNAs conferring resistance to antibiotics, such as G418 and hygromycin B. Cells harboring the vector can be selected on the basis of resistance to these compounds.

**[0086]** Transcriptional and translational control sequences for mammalian host cell expression vectors can be excised from viral genomes. Commonly used promoter sequences and enhancer sequences are derived from polyoma virus, adenovirus 2, simian virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early and late promoter, enhancer, splice, and polyadenylation sites can be used to provide other genetic elements for expression of a structural gene sequence in a mammalian host cell. Viral early and late promoters are particularly useful because both are easily obtained from a viral genome as a fragment, which can also contain a viral origin of replication (Fiers et al., Nature 273:113, 1978; Kaufman, Meth. in Enzymology, 1990). Smaller or larger SV40 fragments can also be used, provided the approximately 250 bp sequence extending from the *Hind* III site toward the *Bgl* I site located in the SV40 viral origin of replication site is included.

**[0087]** Additional control sequences shown to improve expression of heterologous genes from mammalian expression vectors include such elements as the expression augmenting sequence element (EASE) derived from CHO cells (Morris et al., Animal Cell Technology, 1997, pp. 529-534) and the tripartite leader (TPL) and VA gene RNAs from Adenovirus 2 (Gingeras et al., J. Biol. Chem. 257:13475, 1982). The internal ribosome entry site (IRES) sequences of viral origin allows dicistronic mRNAs to be translated efficiently (Oh and Samow, Current Opinion in Genetics and Development 3: 295, 1993; Ramesh et al., Nucleic Acids Research 24:2697, 1996). Expression of a heterologous cDNA as part of a dicistronic mRNA followed by the gene for a selectable marker (e.g. DHFR) has been shown to improve transfectability of the host and expression of the heterologous cDNA (Kaufman, Meth. in Enzymology, 1990). Exemplary expression vectors that employ dicistronic mRNAs are pTR-DC/GFP described by Mosser et al., Biotechniques 22:150, 1997, and p2A5I described by Morris et al., Animal Cell Technology, 1997, pp. 529-534.

**[0088]** A useful high expression vector, pCAVNOT, has been described by Mosley et al., Cell 59:335, 1989. Other expression vectors for use in mammalian host cells can be constructed as disclosed by Okayama and Berg (Mol. Cell. Biol. 3:280, 1983). A useful system for stable high level expression of mammalian cDNAs in C127 murine mammary epithelial cells can be constructed substantially as described by Cosman et al. (Mol. Immunol. 23:935, 1986). A useful high expression vector, PMLSV N1/N4, described by Cosman et al., Nature 312:768, 1984, has been deposited as ATCC 39890. Additional useful mammalian expression vectors are known in the art.

**[0089]** Regarding signal peptides that may be employed in producing TWEAKR polypeptides, the native TWEAKR signal peptide may be used or it may be replaced by a heterologous signal peptide or leader sequence, if desired. The choice of signal peptide or leader may depend on factors such as the type of host cells in which the recombinant TWEAKR is to be produced. Examples of heterologous signal peptides that are functional in mammalian host cells include the signal sequence for interleukin-7 (IL-7) described in United States Patent 4,965,195, the signal sequence for interleukin-2 receptor described in Cosman et al., Nature 312:768 (1984); the interleukin-4 receptor signal peptide described in EP 367,566; the type I interleukin-1 receptor signal peptide described in U.S. Patent 4,968,607; and the type II interleukin-1 receptor signal peptide described in EP 460,846.

**[0090]** Using the techniques of recombinant DNA including mutagenesis and the polymerase chain reaction (PCR), the skilled artisan can produce DNA sequences that encode TWEAKR polypeptides comprising various additions or substitutions of amino acid residues or sequences, or deletions of terminal or internal residues or sequences, including TWEAKR fragments, variants, derivatives, and fusion polypeptides.

**[0091]** Transgenic animals, including mice, goats, sheep, and pigs, and transgenic plants, including tobacco, tomato, legumes, grasses, and grains, may also be used as bioreactors for the production of TWEAKR polypeptides, including soluble TWEAKR polypeptides. In the case of transgenic animals, it is particularly advantageous to construct a chimeric DNA including a TWEAKR coding sequence operably linked to cis-acting regulatory sequences that promote expression of the soluble TWEAKR in milk and/or other body fluids (see, e.g., U.S. Patent No. 5,843,705; U.S. Patent No. 5,880,327). In the case of transgenic plants it is particularly advantageous to produce TWEAKR in a particular cell type, tissue, or organ (see, e.g., US Patent No. 5,639,947; U.S. Patent No. 5,889,189).

**[0092]** The skilled artisan will recognize that the procedure for purifying expressed soluble TWEAKR polypeptides will

vary according to the host system employed, and whether or not the recombinant polypeptide is secreted. Soluble TWEAKR polypeptides may be purified using methods known in the art, including one or more concentration, salting-out, ion exchange, hydrophobic interaction, affinity purification, HPLC, or size exclusion chromatography steps. Fusion polypeptides comprising Fc moieties (and multimers formed therefrom) offer the advantage of facile purification by affinity chromatography over Protein A or Protein G columns.

#### F. Methods of Treatment/Medical Uses

**[0093]** Described below are methods and compositions employing the TWEAK receptor or ligand, or the genes encoding the TWEAK receptor or ligand, to promote or suppress angiogenesis in a target tissue or group of cells. The terms "treat," "treating," "treatment," "therapy," "therapeutic," and the like are intended to include preventative therapy, prophylactic therapy, ameliorative therapy, and curative therapy.

**[0094]** The disclosed polypeptides, compositions, and methods are used to inhibit angiogenesis or other TWEAKR-mediated responses in a mammal in need of such treatment. The term "TWEAKR-mediated response" includes any cellular, physiological, or other biological response that is caused at least in part by the binding of TWEAK ligand to TWEAKR, or which may be inhibited or suppressed, in whole or in part, by blocking TWEAK from binding to TWEAKR. The treatment is advantageously administered in order to prevent the onset or the recurrence of a disease or condition mediated by angiogenesis, or to treat a mammal that has a disease or condition mediated by angiogenesis. Diseases and conditions mediated by angiogenesis include but are not limited to ocular disorders, malignant and metastatic conditions, and inflammatory diseases.

**[0095]** Among the ocular disorders that can be treated according to the present invention are eye diseases characterized by ocular neovascularization including, but not limited to, diabetic retinopathy (a major complication of diabetes), retinopathy of prematurity (this devastating eye condition, that frequently leads to chronic vision problems and carries a high risk of blindness, is a severe complication during the care of premature infants), neovascular glaucoma, retinoblastoma, retrolental fibroplasia, rubeosis, uveitis, macular degeneration, and corneal graft neovascularization. Other eye inflammatory diseases, ocular tumors, and diseases associated with choroidal or iris neovascularization can also be treated according to the present invention.

**[0096]** The present invention can also be for use in treating malignant and metastatic conditions such as solid tumors. Solid tumors include both primary and metastatic sarcomas and carcinomas.

**[0097]** The present invention can also be for use in treating inflammatory diseases including, but not limited to, arthritis, rheumatism, and psoriasis.

**[0098]** Other diseases and conditions that can be treated according to the use of the present invention include benign tumors and preneoplastic conditions, myocardial angiogenesis, hemophilic joints, scleroderma, vascular adhesions, atherosclerotic plaque neovascularization, telangiectasia, and wound granulation.

**[0099]** Disease states that are angiogenic-dependent include coronary or peripheral atherosclerosis and ischemia of any tissue or organ, including the heart, liver, brain, and the like. These types of diseases can be treated by compositions that promote angiogenesis.

**[0100]** In addition to polypeptides comprising a fragment of TWEAKR extracellular domain, soluble TWEAKR multimers, and antibodies that bind to the TWEAKR extracellular domain, other forms of TWEAKR antagonists can also be administered to achieve a therapeutic effect. Examples of other forms of TWEAKR antagonists include other antibodies such as antibodies against TWEAK, antisense nucleic acids, ribozymes, muteins, aptamers, and small molecules directed against TWEAKR or against TWEAK.

**[0101]** The uses according to the present invention can be tested in in vivo animal models to confirm the desired prophylactic or therapeutic activity, as well as to determine the optimal therapeutic dosage, prior to administration to humans.

**[0102]** The amount of a particular TWEAKR antagonist that will be effective in a particular medical use depends upon age, type and severity of the condition to be treated, body weight, desired duration of treatment, method of administration, and other parameters. Effective dosages are determined by a physician or other qualified medical professional. Typical effective dosages are about 0.01 mg/kg to about 100 mg/kg body weight. In some preferred embodiments the dosage is about 0.1-50 mg/kg; in some preferred embodiments the dosage is about 0.5-10 mg/kg. The dosage for local administration is typically lower than for systemic administration. In some embodiments a single administration is sufficient; in some embodiments the TWEAKR antagonist is administered as multiple doses over one or more days.

**[0103]** The TWEAKR antagonists are typically administered in the form of a pharmaceutical composition comprising one or more pharmacologically acceptable carriers. Pharmaceutically acceptable carriers include diluents, fillers, adjuvants, excipients, and vehicles which are pharmaceutically acceptable for the route of administration, and may be aqueous or oleaginous suspensions formulated using suitable dispersing, wetting, and suspending agents.

**[0104]** Pharmaceutically acceptable carriers are generally sterile and free of pyrogenic agents, and may include water, oils, solvents, salts, sugars and other carbohydrates, emulsifying agents, buffering agents, antimicrobial agents, and

chelating agents. The particular pharmaceutically acceptable carrier and the ratio of active compound to carrier are determined by the solubility and chemical properties of the composition, the mode of administration, and standard pharmaceutical practice.

**[0105]** The compositions as described herein may be contained in a vial, bottle, tube, syringe inhaler or other container for single or multiple administrations. Such containers may be made of glass or a polymer material such as polypropylene, polyethylene, or polyvinylchloride, for example. Preferred containers may include a seal, or other closure system, such as a rubber stopper that may be penetrated by a needle in order to withdraw a single dose and then re-seal upon removal of the needle. All such containers for injectable liquids, lyophilized formulations, reconstituted lyophilized formulations or reconstitutable powders for injection known in the art or for the administration of aerosolized compositions are contemplated for use in the presently disclosed compositions and methods.

**[0106]** The TWEAKR antagonists are administered to the patient in a manner appropriate to the indication. Thus, for example, a TWEAKR antagonist, or a pharmaceutical composition thereof, may be administered by intravenous, transdermal, intradermal, intraperitoneal, intramuscular, intranasal, epidural, oral, topical, subcutaneous, intracavity, sustained release from implants, peristaltic routes, or by any other suitable technique. Parenteral administration is preferred.

**[0107]** In certain embodiments of the claimed invention, the use further comprises the use of one or more additional chemotherapeutic agents. The additional chemotherapeutic agent(s) may be administered prior to, concurrently with, or following the administration of the TWEAKR antagonist. The use of more than one chemotherapeutic agent is particularly advantageous when the mammal that is being treated has a solid tumor. In some embodiments of the claimed invention, the treatment further comprises the use of radiation. Radiation, including brachytherapy and teletherapy, may be administered prior to, concurrently with, or following the administration of the second chemotherapeutic agent(s) and/or TWEAKR antagonist.

**[0108]** When the mammal that is being treated has a solid tumor, the use preferably includes in addition to a TWEAKR antagonist, one or more chemotherapeutic agents selected from the group consisting of alkylating agents, antimetabolites, vinca alkaloids and other plant-derived chemotherapeutics, nitrosoureas, antitumor antibiotics, antitumor enzymes, topoisomerase inhibitors, platinum analogs, adrenocortical suppressants, hormones, hormone agonists and antagonists, antibodies, immunotherapeutics, blood cell factors, radiotherapeutics, and biological response modifiers.

**[0109]** In some preferred embodiments the use includes, in addition to a TWEAKR antagonist, one or more chemotherapeutic agents selected from the group consisting of cisplatin, cyclophosphamide, mechlorethamine, melphalan, bleomycin, carboplatin, fluorouracil, 5-fluorodeoxyuridine, methotrexate, taxol, asparaginase, vincristine, and vinblastine, lymphokines and cytokines such as interleukins, interferons (including alpha, beta, or delta), and TNF, chlorambucil, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, cytarabine, mercaptopurine, thioguanine, vindesine, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin, L-asparaginase, hydroxyurea, methylhydrazine, mitotane, tamoxifen, and fluoxymesterone.

**[0110]** In some preferred embodiments the use includes, in addition to a TWEAKR antagonist, one or more chemotherapeutic agents, including various soluble forms thereof, selected from the group consisting of Flt3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-1BB ligand, anti-4-1BB antibodies, TNF antagonists and TNF receptor antagonists, TRAIL, VEGF antagonists, VEGF receptor (including VEGF-R1 and VEGF-R2, also known as Flt1 and Flk1 or KDR) antagonists, Tek antagonists, and CD148 (also referred to as DEP-1, ECRTF, and PTPRJ, see Takahashi et al., J. Am. Soc. Nephrol. 10:2135-45, 1999) agonists. In some preferred embodiments the TWEAKR antagonists of the invention are used as a component of, or in combination with, "metronomic therapy," such as that described by Browder et al. and Klement et al. (Cancer Research 60:1878, 2000; J. Clin. Invest. 105(8):R15, 2000; see also Barinaga, Science 288:245, 2000).

**[0111]** The polypeptides, compositions, and methods may be used as a first line treatment, for the treatment of residual disease following primary therapy, or as an adjunct to other therapies including chemotherapy, surgery, radiation, and other therapeutic methods known in the art.

**[0112]** When the nucleic acid sequences are delivered according to the methods disclosed herein, it is advantageous to use a delivery mechanism so that the sequences will be incorporated into a cell for expression. Delivery systems that may advantageously be employed in the contemplated methods include the use of, for example, viral delivery systems such as retroviral and adenoviral vectors, as well as non-viral delivery systems. Such delivery systems are well known by those skilled in the art.

#### G. Methods of Screening

**[0113]** The TWEAK receptor as described herein may be used in a variety of methods of screening to isolate, for example, TWEAKR agonists and antagonists. TWEAKR agonists are compounds that promote the biological activity of TWEAKR and TWEAKR antagonists are compounds that inhibit the biological activity of TWEAKR. Compounds identified via the following screening assays can be used in compositions and methods for modulating angiogenesis to treat a variety of disease states. The present disclosure provides methods of screening for compounds that (1) modulate TWEAK

receptor or ligand gene expression in a target tissue or cell, (2) modulate the TWEAK receptor-ligand interaction to regulate angiogenesis; (3) bind to the TWEAK receptor or ligand to influence angiogenesis; or (4) interfere with or regulate the bound TWEAK receptor-ligand complex's influence on downstream events such as angiogenesis.

**[0114]** The present invention contemplates the use of assays that are designed to identify compounds that modulate the activity of a TWEAK receptor or ligand gene (i.e., modulate the level of TWEAK gene expression and/or modulate the level of TWEAK gene product activity). Assays may additionally be utilized that identify compounds that bind to TWEAK gene regulatory sequences (e.g., promoter sequences; see e.g., Platt, 1994, J. Biol. Chem. 269, 28558-28562), and that may modulate the level of TWEAK gene expression.

**[0115]** Such an assay may involve, for example, the use of a control system, in which transcription and translation of the TWEAK receptor or ligand gene occurs, in comparison to a system including a test compounds suspected of influencing normal transcription or translation of a TWEAK gene. For example, one could determine the rate of TWEAK receptor RNA produced by cardiac cells, and use this to determine if a test compound influences that rate. To assess the influence of a test compound suspected to influence this normal rate of transcription, one would first determine the rate of TWEAK receptor RNA production in a cardiac cell culture by, for example, Northern Blotting. One could then administer the test compound to a cardiac cell culture under otherwise identical conditions as the control culture. Then the rate of TWEAK receptor RNA in the culture treated with the test compound could be determined by, for example, Northern Blotting, and compared to the rate of TWEAK receptor RNA produced by the control culture cells. An increase in the TWEAK receptor RNA in the cells contacted with the test compound relative to control cells is indicative of a stimulator of TWEAK receptor gene transcription and/or translation in cardiac cells, while a decrease is indicative of an inhibitor of TWEAK receptor gene transcription and/or translation in cardiac cells.

**[0116]** There are a variety of other methods that can be used to determine the level of TWEAK receptor or ligand gene expression as well, and may further be used in assays to determine the influence of a test compound on the level of TWEAK receptor or ligand gene expression. For example, RNA from a cell type or tissue known, or suspected, to express the TWEAK receptor or ligand, gene, such as cardiac, may be isolated and tested utilizing hybridization or PCR techniques. The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the assessment of cells to be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the TWEAK receptor or ligand gene. Such analyses may reveal both quantitative and qualitative aspects of the expression pattern of the TWEAK receptor or ligand gene, including activation or inactivation of TWEAK receptor or ligand gene expression.

**[0117]** Described herein is such a detection scheme, wherein a cDNA molecule is synthesized from an RNA molecule of interest (e.g., by reverse transcription of the RNA molecule into cDNA). A sequence within the cDNA is then used as the template for a nucleic acid amplification reaction, such as a PCR amplification reaction, or the like. The nucleic acid reagents used as synthesis initiation reagents (e.g., primers) in the reverse transcription and nucleic acid amplification steps of this method are chosen from among the TWEAK receptor or ligand gene nucleic acid segments described above. The preferred lengths of such nucleic acid reagents are at least 9-30 nucleotides. For detection of the amplified product, the nucleic acid amplification may be performed using radioactively or non-radioactively labeled nucleotides. Alternatively, enough amplified product may be made such that the product may be visualized by standard ethidium bromide staining or by utilizing any other suitable nucleic acid staining method.

**[0118]** Additionally, it is possible to perform such TWEAK receptor or ligand gene expression assays "in situ", i.e., directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary. TWEAK receptor or ligand gene nucleic acid segments described above can be used as probes and/or primers for such in situ procedures (see, for example, Nuovo, G. J., 1992. "PCR In Situ Hybridization: Protocols And Applications". Raven Press. NY).

**[0119]** Compounds identified via assays such as those described herein may be useful, for example, in modulating angiogenesis influenced by the TWEAK receptor-ligand interaction. Such methods of stimulating or inhibiting TWEAK-influenced angiogenesis are discussed herein.

**[0120]** Alternatively, assay systems may be designed to identify compounds capable of binding the TWEAK receptor or ligand polypeptide of the invention and thereby influencing angiogenesis resulting, from this interaction. Compounds identified may be useful, for example, in modulating the vascularization of target tissues or cells, may be utilized in screens for identifying compounds that disrupt normal TWEAK receptor-ligand interactions, or may in themselves disrupt such interactions.

**[0121]** The principle of the assays used to identify compounds that bind to the TWEAK receptor or ligand involves preparing a reaction mixture of the TWEAK receptor or ligand and the test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex that can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways. For example, one method to conduct such an assay screening for compounds that bind to the TWEAK receptor; would involve anchoring the TWEAK receptor or the test substance onto a solid phase and detecting TWEAK receptor/test compound complexes anchored on the solid phase at the end of the reaction. In such a method, the TWEAK receptor may be anchored onto a solid surface, and the

test compound, which is not anchored, may be labeled, either directly or indirectly. Alternatively, these same methods could be used to screen for test compounds that bind to the TWEAK ligand rather than receptor.

**[0122]** In practice, microtiter plates may conveniently be utilized as the solid phase. The anchored component may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished by simply coating the solid surface with a solution of the protein and drying. Alternatively, an immobilized antibody, preferably a monoclonal antibody, specific for the protein to be immobilized may be used to anchor the protein to the solid surface. The surfaces may be prepared in advance and stored.

**[0123]** In order to conduct the assay, the non-immobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the previously non-immobilized component (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody).

**[0124]** Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for the TWEAK receptor or ligand or the test compound to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.

**[0125]** Those compounds identified as binding agents for either the TWEAK receptor or the TWEAK ligand may further be assessed for their ability to interfere with TWEAK receptor-ligand interaction, as described below, and thereby suppress or promote angiogenesis resulting from TWEAK receptor-ligand interaction. Such compounds may then be used therapeutically to stimulate or inhibit angiogenesis.

**[0126]** The TWEAK receptor and ligand polypeptides may also be used in a screening assay to identify compounds and small molecules which specifically interact with the disclosed TWEAK receptor or ligand to either inhibit (antagonize) or enhance (agonize) interaction between these molecules. Thus, for example, polypeptides of the invention may be used to identify antagonists and agonists from cells, cell-free preparations, chemical libraries, and natural product mixtures. The antagonists and agonists may be natural or modified substrates, ligands, enzymes, receptors, etc. of the polypeptides of the instant invention, or may be structural or functional mimetics of the polypeptides. Potential antagonists of the TWEAK receptor-ligand interaction of the instant invention may include small molecules, peptides and antibodies that bind to and occupy a binding site of the polypeptides, causing them to be unavailable to interact and therefore preventing their normal ability to modulate angiogenesis. Other potential antagonists are antisense molecules which may hybridize to mRNA *in vivo* and block translation of the mRNA into the polypeptides of the instant invention. Potential agonists include small molecules, peptides and antibodies which bind to the instant TWEAK polypeptides and influence angiogenesis as caused by the disclosed interactions of the TWEAK polypeptides of the instant invention.

**[0127]** Small molecule agonists and antagonists are usually less than 10K molecular weight and may possess a number of physiochemical and pharmacological properties that enhance cell penetration, resist degradation and prolong their physiological half-lives. (Gibbs, "pharmaceutical Research in Molecular Oncology," Cell, Vol. 79, (1994).) Antibodies, which include intact molecules as well as fragments such as Fab and F(ab')<sub>2</sub> fragments, may be used to bind to and inhibit the polypeptides of the instant invention by blocking the commencement of a signaling cascade. It is preferable that the antibodies are humanized, and more preferable that the antibodies are human. The antibodies may be prepared by any of a variety of well-known methods.

**[0128]** Specific screening methods are known in the art and many are extensively incorporated in high throughput test systems so that large numbers of test compounds can be screened within a short amount of time. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, cell based assays, etc. These assay formats are well known in the art. The screening assays of the present invention are amenable to screening of chemical libraries and are suitable for the identification of small molecule drug candidates, antibodies, peptides and other antagonists and agonists.

**[0129]** One embodiment of a method for identifying molecules which antagonize or inhibit TWEAK receptor-ligand interaction involves adding a candidate molecule to a medium which contains cells that express the polypeptides of the instant invention: changing the conditions of said medium so that, but for the presence of the candidate molecule, the polypeptides would interact; and observing the binding and inhibition of angiogenesis. Binding of the TWEAK receptor and ligand can be determined according to competitive binding assays outlined above, and well known in the art. The angiogenic effect of this binding can be determined via cell proliferation assays such as, for example, cell density assays, or other cell proliferation assays that are also well-known in the art. The activity of the cells contacted with the candidate molecule may then be compared with the identical cells which were not contacted and agonists and antagonists of the TWEAK polypeptide interactions of the instant invention may be identified. The measurement of biological activity may be performed by a number of well-known methods such as measuring the amount of protein present (e.g. an ELISA) or

of the protein's activity. A decrease in biological stimulation or activation would indicate an antagonist. An increase would indicate an agonist.

**[0130]** Screening assays can further be designed to find molecules that mimic the biological activity resulting from the TWEAK polypeptide interactions of the instant invention. Molecules which mimic the biological activity of a polypeptide may be useful for enhancing the biological activity of the polypeptide. To identify compounds for therapeutically active agents that mimic the biological activity of a polypeptide, it must first be determined whether a candidate molecule binds to the polypeptide. A binding candidate molecule is then added to a biological assay to determine its biological effects. The biological effects of the candidate molecule are then compared to those of the polypeptide.

**[0131]** Additionally, complex formation within reaction mixtures containing the test compound and normal TWEAK receptor or ligand gene protein may also be compared to complex formation within reaction mixtures containing the test compound and a mutant TWEAK receptor or ligand gene protein. This comparison may be important in those cases wherein it is desirable to identify compounds that disrupt interactions of mutant but not normal TWEAK receptor or ligand gene proteins.

**[0132]** The assay for compounds that interfere with the interaction of the TWEAK receptor or ligand gene products and binding partners can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the TWEAK receptor or ligand gene product or the binding partner onto a solid phase and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction between the TWEAK receptor or ligand gene products and the binding partners, e.g., by competition, can be identified by conducting the reaction in the presence of the test substance; i.e., by adding the test substance to the reaction mixture prior to or simultaneously with the TWEAK receptor and ligand gene products. Alternatively, test compounds that disrupt preformed complexes, e.g., compounds with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are described briefly below.

**[0133]** In a heterogeneous assay system, either the TWEAK receptor or ligand gene product, is anchored onto a solid surface, the non-anchored species is labeled, either directly or indirectly. In practice, microtiter plates are conveniently utilized. The anchored species may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished simply by coating the solid surface with a solution of the TWEAK receptor or ligand gene product and drying. Alternatively, an immobilized antibody specific for the species to be anchored may be used to anchor the species to the solid surface. The surfaces may be prepared in advance and stored.

**[0134]** In order to conduct the assay, the partner of the immobilized species is exposed to the coated surface with or without the test compound. After the reaction is complete, unreacted components are removed (e.g., by washing) and any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds that inhibit complex formation or that disrupt preformed complexes can be detected.

**[0135]** Alternatively, the reaction can be conducted in a liquid phase in the presence or absence of the test compound, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes. Again, depending upon the order of addition of reactants to the liquid phase, test compounds that inhibit complex or that disrupt preformed complexes can be identified.

**[0136]** In an alternate embodiment of the invention, a homogeneous assay can be used. In this approach, a preformed complex of the TWEAK receptor or ligand gene product is prepared in which either the TWEAK receptor or ligand gene product or its binding partners is labeled, but the signal generated by the label is quenched due to complex formation (see, e.g., U.S. Pat. No. 4,109,496 by Rubenstein which utilizes this approach for immunoassays). The addition of a test substance that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances that disrupt TWEAK receptor or ligand gene product interaction can be identified.

**[0137]** In a particular embodiment, the TWEAK receptor or ligand gene product can be prepared for immobilization using recombinant DNA techniques. For example, the TWEAK receptor or ligand coding region can be fused to a glutathione-S-transferase (GST) gene using a fusion vector, such as pGEX-5X-1, in such a manner that its binding activity is maintained in the resulting fusion protein. The interactive binding partner can be purified and used to raise a monoclonal antibody, using methods routinely practiced in the art. This antibody can be labeled with the radioactive isotope  $^{125}\text{I}$ , for example, by methods routinely practiced in the art. In a heterogeneous assay, e.g., the GST-TWEAK

receptor or ligand fusion protein can be anchored to glutathione-agarose beads. The TWEAK receptor or ligand gene product can then be added in the presence or absence of the test compound in a manner that allows interaction and binding to occur. At the end of the reaction period, unbound material can be washed away, and the labeled monoclonal antibody can be added to the system and allowed to bind to the complexed components. The interaction between the TWEAK receptor and ligand gene products can be detected by measuring the amount of radioactivity that remains associated with the glutathione-agarose beads. A successful inhibition of the interaction by the test compound will result in a decrease in measured radioactivity.

**[0138]** Alternatively, a GST-TWEAK receptor gene fusion protein and TWEAK ligand gene product (or *vice versa*) can be mixed together in liquid in the absence of the solid glutathione-agarose beads. The test compound can be added either during or after the species are allowed to interact. This mixture can then be added to the glutathione-agarose beads and unbound material is washed away. Again the extent of inhibition of the TWEAK receptor-ligand gene product interaction can be detected by adding the labeled antibody and measuring the radioactivity associated with the beads.

**[0139]** These same techniques can be employed using peptide fragments that correspond to the binding domains of the TWEAK receptor and/or ligand, protein, in place of one or both of the full length proteins. Any number of methods routinely practiced in the art can be used to identify and isolate the binding sites. These methods include, but are not limited to, mutagenesis of the gene encoding one of the proteins and screening for disruption of binding in a co-immunoprecipitation assay. Compensating mutations in the gene encoding the second species in the complex can then be selected. Sequence analysis of the genes encoding the respective proteins will reveal the mutations that correspond to the region of the protein involved in interactive binding. Alternatively, one protein can be anchored to a solid surface using methods described in this Section above, and allowed to interact with and bind to its labeled binding partner, which has been treated with a proteolytic enzyme, such as trypsin. After washing, a short, labeled peptide comprising the binding domain may remain associated with the solid material, which can be isolated and identified by amino acid sequencing. Also, once the gene coding for the segments can be engineered to express peptide fragments of the protein, which can then be tested for binding activity and purified or synthesized.

**[0140]** For example, and not by way of limitation, a TWEAK receptor or ligand gene product can be anchored to a solid material as described, above, in this Section by making a GST-TWEAK receptor or ligand fusion protein and allowing it to bind to glutathione agarose beads. The interactive binding partner obtained can be labeled with a radioactive isotope, such as  $^{35}\text{S}$ , and cleaved with a proteolytic enzyme such as trypsin. Cleavage products can then be added to the anchored GST-TWEAK receptor fusion protein or TWEAK ligand fusion protein and allowed to bind. After washing away unbound peptides, labeled bound material, representing the binding partner binding domain, can be eluted, purified, and analyzed for amino acid sequence by well-known methods. Peptides so identified can be produced synthetically or fused to appropriate facilitative proteins using recombinant DNA technology.

**[0141]** The TWEAK receptor-ligand interactions of the invention, *in vivo*, initiate a cascade of events that either stimulate or suppress angiogenesis in a target group of cell or tissue. Molecules, such as nucleic acid molecules, proteins, or small molecules may, in turn, influence this cascade. Compounds that disrupt the TWEAK receptor-ligand interaction effects in this way may be useful in regulating angiogenesis.

**[0142]** The basic principle of the assay systems used to identify compounds that interfere with the angiogenic or anti-angiogenic effect of TWEAK receptor-ligand interaction involves preparing a reaction mixture containing the TWEAK receptor and ligand under conditions and for a time sufficient to allow the two to interact and bind, thus forming a complex. In order to test a compound for inhibitory activity of the effect of this interaction, the reaction mixture is prepared in the presence and absence of the test compound. The test compound may be initially included in the reaction mixture, or may be added at a time subsequent to the addition of the TWEAK receptor-ligand complex. Control reaction mixtures are incubated without the test compound or with a placebo. The inhibition or potentiation of any effect of the TWEAK complex on vascularization is then detected. Normal angiogenic response in the control reaction, but not in the reaction mixture containing the test compound, indicates that the compound interferes with the cascade of events initiated by the TWEAK receptor-ligand interaction. Enhanced angiogenesis in the test compounds-containing culture indicates a stimulator of the TWEAK receptor-ligand complex effect.

## EXAMPLES

**[0143]** The following examples are intended to illustrate particular embodiments and not to limit the scope of the invention.



## EXAMPLE 1

## Identification of the TWEAK Receptor

## A. Expression Cloning of TWEAK Receptor cDNA

**[0144]** To clone TWEAK Receptor cDNA, an expression vector encoding a growth hormone leader, a leucine zipper multimerization domain, and the C-terminal extracellular domain of human TWEAK (see Chicheportiche et al., J. Biol. Chem. 272(51):32401, 1997) was constructed. This expression vector, which was named pDC409-LZ-TWEAK, comprised the DNA sequence SEQ ID NO:1 and encoded the polypeptide SEQ ID NO:2. pDC409-LZ-TWEAK conditioned supernatants were produced by transient transfection into CV1-EBNA cells. These supernatants were incubated with magnetic beads coated with polyclonal goat anti-mouse antibody that had previously been incubated with a mouse monoclonal antibody against the leucine zipper. Control beads were produced by mixing the coated beads with supernatants from cells transfected with empty vector.

**[0145]** A monolayer of COS cells grown in a T175 flask was transfected with 15 µg of DNA pools of complexity of 100,000 from a HUVEC cDNA expression library. After 2 days these cells were lifted from the flask, and incubated in 1.5 mls of binding media plus 5% non-fat dried milk for 3 hours at 4 degrees C on a rotator wheel. Cells were pre-cleared by adding control beads and rotated at 4 degrees C for an additional 45 minutes after which bead bound cells were removed with a magnet. Pre-clearing was repeated 2-3 times, then TWEAK coated beads were added to the cells and rotated 30 minutes at 4 degrees C. Cells binding the TWEAK beads were separated by use of a magnet and washed 4x in PBS. Plasmid DNA was extracted from these cells by lysing in 0.1% SDS, and electroporating the supernatants in DH101B cells. Colonies were grown overnight on ampicillin selective media. Transformants were pooled and used as a source of plasmid DNA for a further round of panning. After 2 rounds of panning, positive clones were picked from the resulting pool based on their ability to bind TWEAK using a slide binding protocol like that described in Part B, below.

**[0146]** The human TWEAK receptor (also called TWEAKR) cDNA was determined to have the sequence SEQ ID NO: 3, which encodes a 129 residue polypeptide (SEQ ID NO:4). Examination of the sequence predicts a polypeptide having an approximately 78 amino acid extracellular domain (residues 1-78 of SEQ ID NO:4, including the signal peptide), an approximately 23 amino acid transmembrane domain (residues 79-101 of SEQ ID NO:4), and an approximately 28 amino acid intracellular domain (residues 102-139 of SEQ ID NO:4). TWEAKR is the smallest known TNF receptor family member. It has a single cysteine-rich repeat region in the extracellular domain, as compared to the 3-4 repeats of other TNF receptor family members. The TWEAKR polypeptide was previously described as a transmembrane protein encoded by a human liver cDNA clone (WO 98/55508, see also WO 99/61471), but had not been identified as the TWEAK receptor. A murine homolog, the FGF-inducible Fn14 (Meighan-Mantha et al., J. Biol. Chem. 274(46):33166, 1999), is approximately 82% identical to the human protein, as shown by the alignment in Figure 1.

**[0147]** The newly identified TWEAK receptor was tested side by side with DR3 (which had been identified as the TWEAK receptor by Marsters et al., Current Biology 8:525, 1998) for the ability to bind to TWEAK.

## B. The TWEAK Receptor Binds to TWEAK

**[0148]** Slides of COS cells were transfected with expression vectors containing TWEAKR, DR3, or vector without insert (control). After two days the cells were incubated with concentrated supernatants from CV-1 cells transfected with a vector encoding the leucine zipper TWEAK extracellular domain fusion protein. One hour later the cells were washed and probed with an I-125 labeled antibody against the leucine-zipper domain. The slides were washed, fixed, and autoradiography was performed using x-ray film. The TWEAKR transfected cells bound significant amounts of TWEAK. TWEAK did not bind to the cells transfected with DR3 or the control cells. This experiment confirmed that the TWEAKR polypeptide identified in part A above, rather than DR3, is the major receptor for TWEAK. After discovery of the functional TWEAK receptor, other investigators also reported that DR3 is not the major receptor for TWEAK (Kaptein et al., FEBS Lett., 485(2-3):135, 2000). The TWEAK-TWEAKR binding interaction was further characterized by Scatchard analysis.

**[0149]** CV-1 cells were transfected with human full length TWEAK and mixed 1:30 with Raji cells, which do not express TWEAK. The cells were incubated with serial dilutions of 125-I labeled human TWEAK receptor-Fc for 2 hours at 4 degrees Celsius. Free and bound probe was separated by microfuging the samples through a phalate oil mixture in plastic tubes. Supernatants and pellets were gamma-counted. Scatchard analyses of TWEAK ligand binding the TWEAK receptor showed a binding affinity constant (K<sub>a</sub>) of approximately 4.5 x 10<sup>8</sup> M<sup>-1</sup>.

## C. The TWEAK Receptor is Strongly Expressed in Cardiac Tissue

**[0150]** To determine the expression pattern of the TWEAK receptor, Northern blot analyses were performed. Human multiple tissue northern blots were purchased from Clontech (Palo Alto, CA) and probed with P-32 labeled random

primed DNA from the TWEAK receptor coding region. The blots were washed and autoradiography was performed using x-ray film. Results showed that in the adult TWEAKR is strongly expressed in heart, placenta, and some skeletal muscle samples. Strong expression in heart tissue further supports the utility of TWEAKR in the diagnosis and treatment of cardiac disease. In contrast to the adult, the fetal tissues expressed TWEAKR more ubiquitously; TWEAKR transcripts were seen in the lung and liver.

## EXAMPLE 2

### Preparation of TWEAKR Antagonists and Agonists

**[0151]** Because TWEAK induces angiogenesis. TWEAKR agonists (such as agonistic antibodies) may be used to promote angiogenesis and TWEAKR antagonists (such as soluble receptors and antagonistic antibodies) may be used to inhibit angiogenesis.

#### A. Recombinant Production of Soluble TWEAK Receptor-Fc (TWEAKR-Fc) Fusion Polypeptides

**[0152]** To construct a nucleic acid encoding the TWEAKR extracellular domain fused to Fc, a nucleic acid encoding the N-terminal 79 amino acids from TWEAKR, including the leader (signal peptide), was joined to a nucleic acid encoding an Fc portion from human IgG1. Sequences for this construct are shown as SEQ ID NO:6 (nucleic acid) and SEQ ID NO:7 (amino acid). In SEQ ID NO:7, residues 1-27 are the predicted signal peptide (predicted to be cleaved upon secretion from the cell: the actual cleavage site was identified by N-terminal sequence analysis, see below), residues 28-79 are from the cysteine-rich TWEAKR extracellular domain, residues 80-81 are from a BglII cloning site, and the remainder is the Fc portion. Upon insertion into a mammalian expression vector, and expression in and secretion from a mammalian host cells, this construct produced a polypeptide designated TWEAKR-Fc. N-terminal sequence analysis determined that the secreted polypeptide designated TWEAKR-Fc had an N-terminus corresponding to residue 28 (Glu) of SEQ ID NO:7. Anti-angiogenic activity of TWEAKR-Fc was demonstrated using assays such as those described in the following examples. An analogous Fc-fusion construct was prepared using the murine TWEAKR extracellular domain.

#### B. Production of Antibodies that Bind the TWEAKR Extracellular Domain

**[0153]** BALB/c mice are immunized with TWEAKR extracellular domain and spleen cells are collected and used to prepare hybridomas using standard procedures. Hybridoma supernatants are screened, using ELISA, for the ability to bind TWEAKR. Positives are cloned two times, to insure monoclonality, then isotyped and reassayed for reactivity to TWEAKR. Antibodies and antibody derivatives are also prepared using transgenic mice that express human immunoglobulins and through the use of phage display. The resulting antibodies are tested in assays such as those described in the examples below, to characterize their ability to modulate the TWEAK-TWEAKR interaction, TWEAKR signaling, angiogenesis, and other downstream biological activities.

**[0154]** Agonistic antibodies are used to promote TWEAK-induced biological activities such as angiogenesis, and antagonistic antibodies are used to inhibit TWEAK-induced biological activities such as angiogenesis. For some applications, the activity of antagonistic antibodies is augmented by conjugation to a radioisotope, to a plant-, fungus-, or bacterial-derived cytotoxin such as ricin A or diphtheria toxin, or to another chemical poison. And because of the restricted tissue distribution of TWEAKR, antibodies that bind to TWEAKR are particularly useful as targeting agents for imaging or delivering therapeutics to the vasculature. Antibodies that bind TWEAKR can be used, for example, to target a detectable label or chemotherapeutic to the mural cells (pericytes and vascular smooth muscle cells). Detectable labels may include radioisotopes, chemiluminescent and fluorescent compounds, and enzymes. These techniques are useful, for example, in the diagnosis, staging, and treatment of neoplasms.

## EXAMPLE 3

### Activity of TWEAKR-Fc In a Wound Closure Assay

**[0155]** A planar endothelial cell migration (wound closure) assay was used to quantitate the inhibition of angiogenesis by TWEAKR-Fc in vitro. In this assay, endothelial cell migration is measured as the rate of closure of a circular wound in a cultured cell monolayer. The rate of wound closure is linear, and is dynamically regulated by agents that stimulate and inhibit angiogenesis in vivo.

**[0156]** Primary human renal microvascular endothelial cells, HRMEC, were isolated, cultured, and used at the third passage after thawing, as described in Martin et al., In Vitro Cell Dev Biol 33:261, 1997. Replicate circular lesions, "wounds," (600-800 micron diameter) were generated in confluent HRMEC monolayers using a silicon-tipped drill press.

At the time of wounding the medium (DMEM + 1% BSA) was supplemented with 20 ng/ml PMA (phorbol-12-myristate-13-acetate), EGF (4 ng/ml), and 0.150 to 5  $\mu$ g/ml TWEAKR-Fc, or a combination of 40 ng/ml EGF and 0.150 to 5  $\mu$ g/ml TWEAKR-Fc. The residual wound area was measured as a function of time (0-12 hours) using a microscope and image analysis software (Bioquant, Nashville, TN). The relative migration rate was calculated for each agent and combination of agents by linear regression of residual wound area plotted over time. The results are shown in Figures 2-3.

[0157] Compared to hulgG or media+BSA, TWEAKR-Fc inhibited PMA-induced endothelial migration in a dose responsive manner, reducing the rate of migration to unstimulated levels at 5  $\mu$ g/ml (Figure 2). Neither hulgG nor TWEAKR-Fc inhibited basal (uninduced) migration. When HRMEC migration was induced by EGF, TWEAKR-Fc inhibited endothelial migration in a dose-dependent manner, reducing the rate of migration to unstimulated levels at 5  $\mu$ g/ml (Figure 3).

#### EXAMPLE 4

##### Activity of TWEAKR-Fc In a Corneal Pocket Assay

[0158] A mouse corneal pocket assay was used to quantitate the inhibition of angiogenesis by TWEAKR-Fc in vivo. In this assay, agents to be tested for angiogenic or anti-angiogenic activity are immobilized in a slow release form in a hydron pellet, which is implanted into micropockets created in the corneal epithelium of anesthetized mice. Vascularization is measured as the appearance, density, and extent of vessel ingrowth from the vascularized corneal limbus into the normally avascular cornea.

[0159] Hydron pellets, as described in Kenyon et al., Invest Ophthalmol. & Visual Science 37:1625, 1996, incorporated sucralfate with bFGF (90 ng/pellet), bFGF and IgG (14  $\mu$ g/pellet control), or bFGF and TWEAKR-Fc (1.4  $\mu$ g). The pellets were surgically implanted into corneal stromal micropockets created by micro-dissection 1mm medial to the lateral corneal limbus of 6-8 week old male C57BL mice. After five days, at the peak of neovascular response to bFGF, the corneas were photographed, using a Zeiss slit lamp, at an incipient angle of 35-50° from the polar axis in the meridian containing the pellet. Images were digitized and processed by subtractive color filters (Adobe Photoshop 4.0) to delineate established microvessels by hemoglobin content. Image analysis software (Bioquant, Nashville, TN) was used to calculate the fraction of the corneal image that was vascularized, the vessel density within the vascularized area, and the vessel density within the total cornea.

[0160] As shown in Table 1, TWEAKR-Fc (100 pmol) inhibited bFGF (3 pmol)-induced corneal angiogenesis, reducing the vascular density to 50% of that induced by FGF alone or FGF+IgG.

**Table 1**

<b>Effect of TWEAKR-Fc on FGF-induced Angiogenesis in the Mouse Corneal Pocket Assay</b>	
Treatment	Greater than 50% Reduction in Number and Length of Vessels n/total n (%)
FGF alone	0/2 (0%)
FGF+IgG	0/2 (0%)
FGF+TWEAKR-Fc	6/9 (67%)

#### EXAMPLE 5

##### Qualitative TRAF Binding to the TWEAK Receptor (TWEAKR) Cytoplasmic Domain

[0161] Members of the TRAF family are intra-cellular signaling molecules. Several members of the TRAF family are known to associate with members of the TNF receptor family in order to initiate a signaling cascade that activates the NF-kappa-B pathway, resulting in cell activation and proliferation. A qualitative in vitro binding assay was performed to test whether members of the TRAF family of intra-cellular signaling molecules bind to the cytoplasmic domain of TWEAKR and to learn, therefore, whether the small cytoplasmic domain of TWEAKR is capable of mediating a signal into the cell via the TRAF pathway.

[0162] A GST fusion vector consisting of the C-terminal 29 amino acids of TWEAKR fused to glutathione S-transferase was created by sub-cloning the appropriate insert into the pGEX-4T (Amersham Pharmacia Biotech) vector at the BamHI and NotI sites. The product from this vector was expressed in E.coli and bound to sepharose beads as described by Galibert et al., J. Biol. Chem. 273(51):34120, 1998. Similarly constructed beads coated with RANK cytoplasmic domain-GST fusion proteins were used as a positive control, and beads coated with GST alone were used as a negative control. [35S]methionine/cysteine labeled TRAF proteins were produced in reticulocyte lysates (TNT-coupled Reticulocyte Lysate

Systems. Promega) according to the manufacturer's protocol. Reticulocyte lysates containing the labeled TRAF molecules were first pre-cleared using the control beads followed incubation with the indicated fusion protein coated beads in binding buffer (50 mM HEPES [pH 7.4], 250 mM NaCl, 0.25% (v/v) Nonidet P-40, 10% glycerol, 2 mM EDTA) at 4 degrees Celsius for 2 hours. After washing 4x with binding buffer bound TRAF molecules eluted from the beads in SDS-loading buffer, separated by SDS-PAGE, dried and exposed to X-ray film.

[0163] Binding above background levels was seen with TRAFs 1,2 and 3. No binding above background levels was seen with TRAFs 4,5, and 6. The ability of TWEAKR to bind to TRAFs 1,2, and 3 demonstrates that TWEAKR is capable of inducing a signal to the cell via the TRAF pathway, and therefore transmitting a proliferative signal into the host cell. This experiment provides further evidence that TWEAKR is the functional receptor for TWEAK. It also illustrates a further means by which signaling can be inhibited: by disrupting the TRAF-TWEAKR interaction with a small molecule, or by use of a dominant negative variant of the TRAF molecule.

## EXAMPLE 6

### Activity of TWEAKR-Fc in an Endothelial Cell Proliferation Assay

[0164] An endothelial cell proliferation assay was used to quantitate the inhibition of bFGF or TWEAK induced-proliferation by TWEAKR-Fc in vitro. In this assay, endothelial cell proliferation is measured after 4 days of cell growth in microtiter wells using a cell labeling molecule called calcein AM. Esterases expressed by the cells cleave the calcein and cause it to fluoresce when excited at 485 nm. Uncleaved calcein does not fluoresce. The amount of fluorescence is directly related to the number of endothelial cells in the culture well. Endothelial cell proliferation is often regulated by agents that stimulate and/or inhibit angiogenesis in vivo.

[0165] Primary HUVEC (human umbilical vein endothelial cells) were obtained from a commercial source (Clonetics, Walkersville, MD), cultured, and used at passage 2 to 7. Replicate cultures were set up by adding 3000 HUVEC to each microtiter well in endothelial cell basal media (EBM, an endothelial cell basal media that contains no growth factors or serum and is based on the media formulations developed by Dr. Richard Ham at the University of Colorado, Clonetics) plus 0.05% FBS (fetal bovine serum). At the time of culture initiation FGF-2 (fibroblast growth factor-2, 10 ng/ml) or human TWEAK (100 ng/ml) was added to the cultures in the presence of human IgG (hulgG, control) or human TWEAKR-Fc at concentrations ranging from 0.08  $\mu$ g/ml to 20  $\mu$ g/ml (0.25 to 20  $\mu$ g/ml for TWEAK-induced and 0.08 to 6.7  $\mu$ g/ml for FGF-2-induced). The HUVEC containing cultures were incubated for 4 days at 37 degrees C, 5% CO<sub>2</sub>. On the fourth day of culture 4  $\mu$ M calcein-AM was added to the cultures and 2 hours later the wells were evaluated for fluorescence. The results, expressed as the average fluorescence (485-530 nm) counts for replicate wells plus or minus the SEM. are shown in Figures 4 and 5.

[0166] TWEAKR-Fc specifically inhibited TWEAK-induced HUVEC proliferation in a dose-dependent manner when compared to hulgG which did not effect TWEAK-induced proliferation (Figure 4). In addition, TWEAKR-Fc inhibited the basal proliferation of HUVEC observed during culture in EBM plus 0.05% FBS, as compared to hulgG which did not. Interestingly, TWEAKR-Fc also inhibited FGF-2 mediated HUVEC proliferation at concentrations of greater than 2  $\mu$ g/ml, as compared to hulgG which did not effect the FGF-2 induced HUVEC proliferative response (Figure 5). These results show that TWEAKR-Fc inhibits HUVEC proliferation induced by the addition of exogenous recombinant human TWEAK. That TWEAKR-Fc partially inhibits serum-induced HUVEC-proliferation indicates HUVEC produce endogenous TWEAK that promotes growth/survival of the EC (endothelial cell) via the TWEAKR. TWEAKR-Fc attenuation of FGF-2 induced proliferation indicates that at least part of the EC response to FGF-2 is dependent on endogenous TWEAK/TWEAKR interaction.

## EXAMPLE 7

### Inhibition of Neovascularization by TWEAKR Antagonists in a Murine Cardiac Ischemia/Engraftment Model

[0167] Survival of heterotopically transplanted cardiac tissue from one mouse donor to the ear skin of another genetically similar mouse requires adequate neovascularization by the transplanted heart and the surrounding tissue, to promote survival and energy for cardiac muscle function. Inadequate vasculature at the site of transplant causes excessive ischemia to the heart, tissue damage, and failure of the tissue to engraft. Agents that antagonize factors involved in endothelial cell migration and vessel formation can decrease angiogenesis at the site of transplant, thereby limiting graft tissue function and ultimately engraftment itself. A murine heterotopic cardiac isograft model is used to demonstrate the effects of TWEAKR antagonists, including antibodies and TWEAKR-Fc, on neovascularization.

[0168] Female BALB/c (=12 weeks of age) recipients are given neonatal heart grafts from donor mice of the same strain. The donor heart tissue is grafted into the left ear pinnae of the recipient on day 0 and the mice are divided into two groups. The control group receives human IgG (Hu IgG) the other group receives the TWEAKR antagonist, both

intraperitoneally. The treatments are continued for five consecutive days. The functionality of the grafts is determined by monitoring visible pulsatile activity on days 7 and 14 post-engraftment. The inhibition of functional engraftment, as a function of the dose of TWEAKR antagonist, is determined. The histology of the transplanted hearts is examined in order to visualize the effects of the TWEAKR antagonist on edema at the site of transplant and host and donor tissue vasculature (using, e.g., Factor VIII staining).

## EXAMPLE 6

### Treatment of Tumors With TWEAKR Antagonists

**[0169]** TWEAKR antagonists, including antibodies and TWEAKR-Fc, are tested in animal models of solid tumors. The effect of the TWEAKR antagonists is determined by measuring tumor frequency and tumor growth.

**[0170]** The examples presented above are not intended to be exhaustive or to limit the scope of the invention. The skilled artisan will understand that variations and modifications and variations are possible in light of the above teachings, and such modifications and variations are intended to be within the scope of the invention.

### SEQUENCE LISTING

#### [0171]

<110> WILEY, Steven R. IMMUNEX CORPORATION

<120> TWEAK Receptor

<130> 2968-WO

<140> to be assigned

<141> 2000-12-19

<150> 60/172,878

<151> 1999-12-20

<150> 60/203,347

<151> 2000-05-10

<160> 7

<170> PatentIn Ver. 2.0

<210> 1

<211> 898

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (52)..(873)

<220>

<223> Description of Artificial Sequence: human TWEAK fusion protein construct

<400> 1

EP 1 239 869 B1

	tctc	gagggc	cacgcgttta	aacgtc	gagg	tac	tatccc	gggc	cgccac	c	atg	gct	57				
											Met	Ala					
											1						
5	aca	ggc	tcc	cgg	acg	tcc	ctg	ctc	ctg	gct	ttt	ggc	ctg	ctc	tgc	ctg	105
	Thr	Gly	Ser	Arg	Thr	Ser	Leu	Leu	Leu	Ala	Phe	Gly	Leu	Leu	Cys	Leu	
			5						10				15				
10	ccc	tgg	ctt	caa	gag	ggc	agt	gca	act	agt	tct	gac	cgt	atg	aaa	cag	153
	Pro	Trp	Leu	Gln	Glu	Gly	Ser	Ala	Thr	Ser	Ser	Asp	Arg	Met	Lys	Gln	
		20					25					30					
15	ata	gag	gat	aag	atc	gaa	gag	atc	cta	agt	aag	att	tat	cat	ata	gag	201
	Ile	Glu	Asp	Lys	Ile	Glu	Glu	Ile	Leu	Ser	Lys	Ile	Tyr	His	Ile	Glu	
	35					40					45				50		
20	aat	gaa	atc	gcc	cgt	atc	aaa	aag	ctg	att	ggc	gag	cgg	act	aga	tct	249
	Asn	Glu	Ile	Ala	Arg	Ile	Lys	Lys	Leu	Ile	Gly	Glu	Arg	Thr	Arg	Ser	
				55					60						65		
25	agt	ttg	ggg	agc	cgg	gca	tcg	ctg	tcc	gcc	cag	gag	cct	gcc	cag	gag	297
	Ser	Leu	Gly	Ser	Arg	Ala	Ser	Leu	Ser	Ala	Gln	Glu	Pro	Ala	Gln	Glu	
				70					75					80			
30																	
35																	
40																	
45																	
50																	
55																	

EP 1 239 869 B1

	gag ctg gtg gca gag gag gac cag gac ccg tcg gaa ctg aat ccc cag	345
	Glu Leu Val Ala Glu Glu Asp Gln Asp Pro Ser Glu Leu Asn Pro Gln	
	85 90 95	
5	aca gaa gaa agc cag gat cct gcg cct ttc ctg aac cga cta gtt cgg	393
	Thr Glu Glu Ser Gln Asp Pro Ala Pro Phe Leu Asn Arg Leu Val Arg	
	100 105 110	
10	cct cgc aga agt gca cct aaa ggc cgg aaa aca cgg gct cga aga gcg	441
	Pro Arg Arg Ser Ala Pro Lys Gly Arg Lys Thr Arg Ala Arg Arg Ala	
	115 120 125 130	
15	atc gca gcc cat tat gaa gtt cat cca cga cct gga cag gac gga gcg	489
	Ile Ala Ala His Tyr Glu Val His Pro Arg Pro Gly Gln Asp Gly Ala	
	135 140 145	
20	cag gca ggt gtg gac ggg aca gtg agt ggc tgg gag gaa gcc aga atc	537
	Gln Ala Gly Val Asp Gly Thr Val Ser Gly Trp Glu Glu Ala Arg Ile	
	150 155 160	
25	aac agc tcc agc cct ctg cgc tac aac cgc cag atc ggg gag ttt ata	585
	Asn Ser Ser Ser Pro Leu Arg Tyr Asn Arg Gln Ile Gly Glu Phe Ile	
	165 170 175	
30	gtc acc cgg gct ggg ctc tac tac ctg tac tgt cag gtg cac ttt gat	633
	Val Thr Arg Ala Gly Leu Tyr Tyr Leu Tyr Cys Gln Val His Phe Asp	
	180 185 190	
35	gag ggg aag gct gtc tac ctg aag ctg gac ttg ctg gtg gat ggt gtg	681
	Glu Gly Lys Ala Val Tyr Leu Lys Leu Asp Leu Leu Val Asp Gly Val	
	195 200 205 210	
40	ctg gcc ctg cgc tgc ctg gag gaa ttc tca gcc act gcg gcc agt tcc	729
	Leu Ala Leu Arg Cys Leu Glu Glu Phe Ser Ala Thr Ala Ala Ser Ser	
	215 220 225	
45	ctc ggg ccc cag ctc cgc ctc tgc cag gtg tct ggg ctg ttg gcc ctg	777
	Leu Gly Pro Gln Leu Arg Leu Cys Gln Val Ser Gly Leu Leu Ala Leu	
	230 235 240	
50	cgg cca ggg tcc tcc ctg cgg atc cgc acc ctc ccc tgg gcc cat ctc	825
	Arg Pro Gly Ser Ser Leu Arg Ile Arg Thr Leu Pro Trp Ala His Leu	
	245 250 255	
55	aag gct gcc ccc ttc ctc acc tac ttc gga ctc ttc cag gtt cac tga	873
	Lys Ala Ala Pro Phe Leu Thr Tyr Phe Gly Leu Phe Gln Val His	
	260 265 270	
	gcggccgcgg atctgttttaa actag	898
50	<210> 2	
	<211> 273	
	<212> PRT	
	<213> Artificial Sequence	
55	<220>	
	<223> Description of Artificial Sequence: human TWEAK fusion protein construct	
	<400> 2	

EP 1 239 869 B1

Met Ala Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu  
1 5 10 15

5 Cys Leu Pro Trp Leu Gln Glu Gly Ser Ala Thr Ser Ser Asp Arg Met  
20 25 30

Lys Gln Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His  
35 40 45

10 Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Thr  
50 55 60

Arg Ser Ser Leu Gly Ser Arg Ala Ser Leu Ser Ala Gln Glu Pro Ala  
65 70 75 80

15 Gln Glu Glu Leu Val Ala Glu Glu Asp Gln Asp Pro Ser Glu Leu Asn  
85 90 95

20 Pro Gln Thr Glu Glu Ser Gln Asp Pro Ala Pro Phe Leu Asn Arg Leu  
100 105 110

Val Arg Pro Arg Arg Ser Ala Pro Lys Gly Arg Lys Thr Arg Ala Arg  
115 120 125

25 Arg Ala Ile Ala Ala His Tyr Glu Val His Pro Arg Pro Gly Gln Asp  
130 135 140

Gly Ala Gln Ala Gly Val Asp Gly Thr Val Ser Gly Trp Glu Glu Ala  
145 150 155 160

30 Arg Ile Asn Ser Ser Ser Pro Leu Arg Tyr Asn Arg Gln Ile Gly Glu  
165 170 175

Phe Ile Val Thr Arg Ala Gly Leu Tyr Tyr Leu Tyr Cys Gln Val His  
180 185 190

35 Phe Asp Glu Gly Lys Ala Val Tyr Leu Lys Leu Asp Leu Leu Val Asp  
195 200 205

Gly Val Leu Ala Leu Arg Cys Leu Glu Glu Phe Ser Ala Thr Ala Ala  
210 215 220

40 Ser Ser Leu Gly Pro Gln Leu Arg Leu Cys Gln Val Ser Gly Leu Leu  
225 230 235 240

45 Ala Leu Arg Pro Gly Ser Ser Leu Arg Ile Arg Thr Leu Pro Trp Ala  
245 250 255

His Leu Lys Ala Ala Pro Phe Leu Thr Tyr Phe Gly Leu Phe Gln Val  
260 265 270

50 His

<210> 3

<211> 868

55 <212> DNA

<213> Homo sapiens

<220>



## EP 1 239 869 B1

&lt;221&gt; CDS

&lt;222&gt; (53)..(442)

&lt;400&gt; 3

5 gcttgaattc aataactata acggtcctaa ggtagcgaag aggacgtgca ct atg gct 58  
Met Ala  
1

10 cgg ggc tgc ctg cgc cgg ttg ctg cgg ctc ctc gtg ctg ggg ctc tgg 106  
Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly Leu Trp  
5 10 15

15 ctg gcg ttg ctg cgc tcc gtg gcc ggg gag caa gcg cca ggc acc gcc 154  
Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly Thr Ala  
20 25 30

20 ccc tgc tcc cgc ggc agc tcc tgg agc gcg gac ctg gac aag tgc atg 202  
Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys Cys Met  
35 40 45 50

25 gac tgc gcg tct tgc agg gcg cga ccg cac agc gac ttc tgc ctg ggc 250  
Asp Cys Ala Ser Cys Arg Ala Arg Pro His Ser Asp Phe Cys Leu Gly  
55 60 65

30 tgc gct gca gca cct cct gcc ccc ttc cgg ctg ctt tgg ccc atc ctt 298  
Cys Ala Ala Ala Pro Pro Ala Pro Phe Arg Leu Leu Trp Pro Ile Leu  
70 75 80

35 ggg ggc gct ctg agc ctg acc ttc gtg ctg ggg ctg ctt tct ggc ttt 346  
Gly Gly Ala Leu Ser Leu Thr Phe Val Leu Gly Leu Leu Ser Gly Phe  
85 90 95

40 ttg gtc tgg aga cga tgc cgc agg aga gag aag ttc acc acc ccc ata 394  
Leu Val Trp Arg Arg Cys Arg Arg Arg Glu Lys Phe Thr Thr Pro Ile  
100 105 110

45 gag gag acc ggc gga gag ggc tgc cca gct gtg gcg ctg atc cag tga 442  
Glu Glu Thr Gly Gly Glu Gly Cys Pro Ala Val Ala Leu Ile Gln  
115 120 125 130

50 caatgtgccc cctgccagcc ggggctcgcc cactcatcat tcattcatcc attctagagc 502

55 cagtctctgc ctcccagacg cggcggggagc caagctcctc caaccacaag ggggggtgggg 562

ggcgggtgaat cacctctgag gcctgggccc aggggttcagg ggaaccttcc aaggtgtctg 622

gttgccctgc ctctggctcc agaacagaaa gggagcctca cgctggctca cacaaaacag 682

ctgacactga ctaaggaact gcagcatttg cacaggggag ggggggtgccc tccttcctag 742

aggccctggg ggccaggctg acttgggggg cagacttgac actaggcccc actcactcag 802

atgtcctgaa attccaccac ggggggtcacc ctgggggggtt agggacctat ttttaacact 862

agaggg 868

&lt;210&gt; 4

&lt;211&gt; 129

EP 1 239 869 B1

<212> PRT

<213> Homo sapiens

<400> 4

5  
Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly  
1 5 10 15  
10 Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly  
20 25 30  
Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys  
35 40 45  
15 Cys Met Asp Cys Ala Ser Cys Arg Ala Arg Pro His Ser Asp Phe Cys  
50 55 60  
Leu Gly Cys Ala Ala Ala Pro Pro Ala Pro Phe Arg Leu Leu Trp Pro  
65 70 75 80  
20 Ile Leu Gly Gly Ala Leu Ser Leu Thr Phe Val Leu Gly Leu Leu Ser  
85 90 95  
Gly Phe Leu Val Trp Arg Arg Cys Arg Arg Arg Glu Lys Phe Thr Thr  
100 105 110  
25 Pro Ile Glu Glu Thr Gly Gly Glu Gly Cys Pro Ala Val Ala Leu Ile  
115 120 125  
30 Gln

<210> 5

<211> 129

<212> PRT

35 <213> Mus sp.

<400> 5

40

45

50

55

# EP 1 239 869 B1

	Met	Ala	Pro	Gly	Trp	Pro	Arg	Ser	Leu	Pro	Gln	Ile	Leu	Val	Leu	Gly
	1				5					10					15	
5	Phe	Gly	Leu	Val	Leu	Met	Arg	Ala	Ala	Ala	Gly	Glu	Gln	Ala	Pro	Gly
				20					25					30		
	Thr	Ser	Pro	Cys	Ser	Ser	Gly	Ser	Ser	Trp	Ser	Ala	Asp	Leu	Asp	Lys
			35					40					45			
10	Cys	Met	Asp	Cys	Ala	Ser	Cys	Pro	Ala	Arg	Pro	His	Ser	Asp	Phe	Cys
		50					55					60				
	Leu	Gly	Cys	Ala	Ala	Ala	Pro	Pro	Ala	His	Phe	Arg	Leu	Leu	Trp	Pro
15	65					70				75						80
	Ile	Leu	Gly	Gly	Ala	Leu	Ser	Leu	Val	Leu	Val	Leu	Ala	Leu	Val	Ser
					85				90						95	
	Ser	Phe	Leu	Val	Trp	Arg	Arg	Cys	Arg	Arg	Arg	Glu	Lys	Phe	Thr	Thr
20				100					105					110		
	Pro	Ile	Glu	Glu	Thr	Gly	Gly	Glu	Gly	Cys	Pro	Gly	Val	Ala	Leu	Ile
			115					120					125			
25	Gln															

<210> 6

<211> 932

<212> DNA

30 <213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(930)

35

<220>

<223> Description of Artificial Sequence: human TWEAK receptor fusion protein construct

<400> 6

40

45

50

55

EP 1 239 869 B1

	atg gct cgg ggc tcg ctg cgc cgg ttg ctg cgg ctc ctc gtg ctg ggg	48
	Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly	
	1 5 10 15	
5	ctc tgg ctg gcg ttg ctg cgc tcc gtg gcc ggg gag caa gcg cca ggc	96
	Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly	
	20 25 30	
10	acc gcc ccc tgc tcc cgc ggc agc tcc tgg agc gcg gac ctg gac aag	144
	Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys	
	35 40 45	
15	tgc atg gac tgc gcg tct tgc agg gcg cga ccg cac agc gac ttc tgc	192
	Cys Met Asp Cys Ala Ser Cys Arg Ala Arg Pro His Ser Asp Phe Cys	
	50 55 60	
20	ctg ggc tgc gct gca gca cct cct gcc ccc ttc cgg ctg ctt tgg aga	240
	Leu Gly Cys Ala Ala Ala Pro Pro Ala Pro Phe Arg Leu Leu Trp Arg	
	65 70 75 80	
25	tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa gcc	288
	Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala	
	85 90 95	
30	gag ggc gcg ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc	336
	Glu Gly Ala Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr	
	100 105 110	
35	ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg	384
	Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val	
	115 120 125	
40	agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg	432
	Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val	
	130 135 140	
45	gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc	480
	Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser	
	145 150 155 160	
50	acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg	528
	Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu	
	165 170 175	

EP 1 239 869 B1

	aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc	576
	Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala	
	180 185 190	
5	ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca	624
	Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro	
	195 200 205	
10	cag gtg tac acc ctg ccc cca tcc cgg gag gag atg acc aag aac cag	672
	Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln	
	210 215 220	
15	gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc	720
	Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala	
	225 230 235 240	
20	gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg	768
	Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr	
	245 250 255	
	cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tat agc aag ctc	816
	Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu	
	260 265 270	
25	acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc	864
	Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser	
	275 280 285	
30	gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc	912
	Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser	
	290 295 300	
35	ctg tct ccg ggt aaa tga ac	932
	Leu Ser Pro Gly Lys	
	305 310	

<210> 7

<211> 309

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: human TWEAK receptor fusion protein construct

<400> 7

EP 1 239 869 B1

	Met	Ala	Arg	Gly	Ser	Leu	Arg	Arg	Leu	Leu	Arg	Leu	Leu	Val	Leu	Gly	
	1				5					10					15		
5	Leu	Trp	Leu	Ala	Leu	Leu	Arg	Ser	Val	Ala	Gly	Glu	Gln	Ala	Pro	Gly	
				20					25					30			
	Thr	Ala	Pro	Cys	Ser	Arg	Gly	Ser	Ser	Trp	Ser	Ala	Asp	Leu	Asp	Lys	
			35					40					45				
10	Cys	Met	Asp	Cys	Ala	Ser	Cys	Arg	Ala	Arg	Pro	His	Ser	Asp	Phe	Cys	
		50					55					60					
	Leu	Gly	Cys	Ala	Ala	Ala	Pro	Pro	Ala	Pro	Phe	Arg	Leu	Leu	Trp	Arg	
	65					70					75					80	
15																	
	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Ala	
					85				90						95		
20	Glu	Gly	Ala	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	
				100					105					110			
	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	
				115				120					125				
25	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	
				130			135					140					
	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	
	145					150					155					160	
30																	
	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	
					165					170					175		
	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	
35				180					185					190			
	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	
				195				200					205				
40	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	
		210					215					220					
	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	
	225					230				235					240		
45																	
	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	
					245					250					255		
	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	
50				260					265					270			
	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	
				275				280					285				
55	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	
		290					295					300					
	Leu	Ser	Pro	Gly	Lys												
	305																

## Claims

1. Use of an isolated polypeptide comprising a soluble fragment of the TWEAK receptor extracellular domain that has the ability to bind TWEAK in the manufacture of a medicament for use in inhibiting angiogenesis in a mammal, wherein the TWEAK receptor extracellular domain consists of the sequence as set out in residues 28 to 79 of SEQ ID NO: 7.
2. Use of an antibody that specifically binds to the TWEAK receptor extracellular domain in the manufacture of a medicament for use in modulating angiogenesis in a mammal, wherein the TWEAK receptor extracellular domain consists of the sequence as set out in residues 28 to 79 of SEQ ID NO: 7.
3. The use, as claimed in claim 1 or claim 2, wherein the mammal is a human.
4. The use, as claimed in claim 1, wherein the polypeptide comprises an Fc polypeptide or leucine zipper domain.
5. The use, as claimed in claim 2, wherein the antibody is selected from the group consisting of monoclonal antibodies, humanised antibodies, transgenic antibodies and human antibodies.
6. The use, as claimed in claim 2 or claim 5, wherein the antibody is conjugated to a radioisotope, to a plant-, fungus-, or bacterial-derived toxin such as ricin A or diphtheria toxin, or to another chemical poison.
7. The use, as claimed in claim 1 or claim 2 wherein the polypeptide or the antibody disrupts the interaction between the TWEAK receptor and a TRAF molecule.
8. The use, as claimed in any one of claims 1 to 7, further comprising treating the mammal with a chemotherapeutic agent.
9. Use, as claimed in claim 8, wherein the chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, vinca alkaloids and other plant-derived chemotherapeutics, nitrosoureas, antitumour antibiotics, antitumour enzymes, topoisomerase inhibitors, platinum analogs, adrenocortical suppressants, hormones, hormone agonists, hormone antagonists, antibodies, immunotherapeutics, blood cell factors, radiotherapeutics and biological response modifiers.
10. The use, as claimed in claim 8, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, mechlorethamine, melphalan, bleomycin, carboplatin, fluorouracil, 5-fluorodeoxyuridine, methotrexate, taxol, asparaginase, vincristine, and vinblastine, lymphokines and cytokines such as interleukins, interferons (including alpha, beta, or delta), and TNF, chlorambucil, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, cytarabine, mercaptopurine, thioguanine, vindesine, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin, L-asparaginase, hydroxyurea, methylhydrazine, mitotane, tamoxifen, and fluoxymesterone.
11. The use, as claimed in claim 8, wherein the chemotherapeutic agent is selected from the group consisting of Flt3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-1BB ligand, anti-4-1BB antibodies, TNF antagonists and TNF receptor antagonists, TRAIL, CD148 agonists, VEGF antagonists, VEGF receptor antagonists, and Tek antagonists.
12. The use, as claimed in claim 2 for promoting angiogenesis.
13. The use, as claimed in claim 1 or claim 2 for inhibiting angiogenesis.
14. The use of an antibody, as claimed in any one of claim 2 to 13 for:
  - (a) treating a vascularization deficiency in cardiac or peripheral tissue, including coronary artery disease, myocardial ischemia, myocardial infarction, angina pectoris, peripheral circulation deficits, limb ischemia/reperfusion injury;
  - (b) enhancing wound healing, organ transplantation, reconnection of severed digits or limbs, or vascular or skin grafting; or
  - (c) use in conjunction with bypass surgery or angioplasty.

15. A TWEAKR antagonist comprising an isolated polypeptide comprising a soluble fragment of a TWEAK receptor extracellular domain that has the ability to bind to TWEAK for use in medicine, wherein the TWEAK receptor extracellular domain consists of the sequence as set out in residues 28 to 79 of SEQ ID NO: 7.
- 5 16. A method of identifying a compound that is capable of modulating angiogenesis, the method comprising identifying a test compound that binds to a TWEAK receptor extracellular domain, wherein the test compound is not TWEAK, and wherein the TWEAK receptor extracellular domain consists of the sequence as set out in residues 28 to 79 of SEQ ID NO:7.
- 10 17. A method of claim 16, the method comprising identifying a test compound that affects the interaction between TWEAK and a TWEAK receptor extracellular domain, wherein the TWEAK receptor extracellular domain consists of the sequence as set out in residues 28 to 79 of SEQ ID NO: 7.
- 15 18. A method of identifying a compound that is capable of modulating angiogenesis, the method comprising identifying a test compound that modulates angiogenesis by modulating the interaction between a TWEAK receptor and TRAF, wherein the TWEAK receptor comprises an extracellular domain consisting of the sequence set out in residues 28 to 79 of SEQ ID NO:7.
- 20 19. The method of one of claims 16-18 further comprising determining the ability of the test compound to modulate endothelial cell proliferation and/or endothelial cell migration and/or angiogenesis.
- 25 20. The method of one of claims 17-19, wherein the modulation is stimulatory.
21. The method of one of claims 17-19, wherein the modulation is inhibitory.

#### Patentansprüche

- 30 1. Verwendung eines isolierten Polypeptids, umfassend ein lösliches Fragment der extrazellulären TWEAK-Rezeptordomäne, welche die Fähigkeit zur Bindung von TWEAK aufweist, in der Herstellung eines Medikaments zur Verwendung in der Hemmung der Angiogenese in einem Säuger, wobei die extrazelluläre TWEAK-Rezeptordomäne aus der Sequenz besteht, wie dargestellt durch Reste 28 bis 79 der SEQ ID NR. 7.
- 35 2. Verwendung eines Antikörpers, der an die extrazelluläre TWEAK-Rezeptordomäne spezifisch bindet, in der Herstellung eines Medikaments zur Verwendung im Modulieren der Angiogenese in einem Säuger, wobei die extrazelluläre TWEAK-Rezeptordomäne aus der Sequenz besteht, wie dargestellt durch Reste 28 bis 79 der SEQ ID NR. 7.
- 40 3. Verwendung, wie in Anspruch 1 oder Anspruch 2 beansprucht, wobei der Säuger ein Mensch ist.
- 45 4. Verwendung, wie in Anspruch 1 beansprucht, wobei das Polypeptid ein Fc-Polypeptid oder eine Leucin-Zipper-Domäne umfasst.
- 50 5. Verwendung, wie in Anspruch 2 beansprucht, wobei der Antikörper ausgewählt ist aus der Gruppe, bestehend aus monoklonalen Antikörpern, humanisierten Antikörpern, transgenen Antikörpern und humanen Antikörpern.
- 55 6. Verwendung, wie in Anspruch 2 oder Anspruch 5 beansprucht, wobei der Antikörper an ein Radioisotop, an ein von Pflanzen, Pilzen oder Bakterien stammendes Toxin, wie etwa Ricin A oder Diphtherietoxin, oder an ein anderes chemisches Gift konjugiert ist.
7. Verwendung, wie in Anspruch 1 oder Anspruch 2 beansprucht, wobei das Polypeptid oder der Antikörper die Wechselwirkung zwischen dem TWEAK-Rezeptor und einem TRAF-Molekül unterbricht.
8. Verwendung, wie in jedem der Ansprüche 1 bis 7 beansprucht, weiters umfassend die Behandlung des Säugers mit einem chemotherapeutischen Mittel.
9. Verwendung, wie in Anspruch 8 beansprucht, wobei das chemotherapeutische Mittel ausgewählt ist aus der Gruppe, bestehend aus Alkylierungsmitteln, Antimetaboliten, Vincaalkaloiden und anderen von Pflanzen stammenden Chemotherapeutika, Nitrosoharnstoffen, Antitumor-Antibiotika, Antitumorenzymen, Topoisomerasehemmern, Plat-



inanaloga, adrenokortikalen Suppressiva, Hormonen, Hormonagonisten, Hormonantagonisten, Antikörpern, Immuntherapeutika, Blutzellfaktoren, Radiotherapeutika und Modifikatoren der biologischen Reaktion.

- 5 10. Verwendung, wie in Anspruch 8 beansprucht, wobei das chemotherapeutische Mittel ausgewählt ist aus der Gruppe, bestehend aus Cisplatin, Cyclophosphamid, Mechlorethamin, Melphalan, Bleomycin, Carboplatin, Fluoruracil, 5-Fluordesoxyuridin, Methotrexat, Taxol, Asparaginase, Vincristin und Vinblastin, Lymphokinen und Zytokinen, wie etwa Interleukinen, Interferonen (einschließlich alpha, beta oder delta), und TNF, Chlorambucil, Busulfan, Carmustin, Lomustin, Semustin, Streptozocin, Dacarbacin, Cytarabin, Mercaptopurin, Thioguanin, Vindesin, Etoposid, Teniposid, Datinomycin, Daunorubicin, Doxorubicin, Bleomycin, Plicamycin, Mitomycin, L-Asparaginase, Hydroxy-Harnstoff, Methylhydrazin, Mitotan, Tamoxifen und Fluoxymesteron.
- 15 11. Verwendung, wie in Anspruch 8 beansprucht, wobei das chemotherapeutische Mittel ausgewählt ist aus der Gruppe, bestehend aus Flt3-Ligand, CD40-Ligand, Interleukin-2, Interleukin-12, 4-1BB-Ligand, Anti-4-1BB-Antikörpern, TNF-Antagonisten und TNF-Rezeptor-Antagonisten, TRAIL, CD148-Agonisten, VEGF-Antagonisten, VEGF-Rezeptor-Antagonisten und Tek-Antagonisten.
- 20 12. Verwendung, wie in Anspruch 2 beansprucht, zur Förderung der Angiogenese.
13. Verwendung, wie in Anspruch 1 oder Anspruch 2 beansprucht, zur Hemmung der Angiogenese.
- 25 14. Verwendung eines Antikörpers, wie in jedem der Ansprüche 2 bis 13 beansprucht, zur:
  - (a) Behandlung eines Vaskularisationsmangels in kardialen oder peripherem Gewebe, einschließlich einer Koronararterienerkrankung, Myokardischämie, Myokardinfarkt, Angina pectoris, peripheren Zirkulationsstörungen, Gliedmaßenischämie/ Reperfusionsverletzung;
  - (b) Förderung der Wundheilung, Organtransplantation, Replantation abgetrennter Finger oder Gliedmaßen, oder Gefäß- oder Hauttransplantation; oder
  - (c) Verwendung in Verbindung mit einer Bypass-Operation oder Angioplastie.
- 30 15. TWEAK-R-Antagonist, umfassend ein isoliertes Polypeptid, welches ein lösliches Fragment einer extrazellulären TWEAK-Rezeptordomäne, die die Fähigkeit zur Bindung von TWEAK aufweist, umfasst, zur Verwendung in der Medizin, wobei die extrazelluläre TWEAK-Rezeptordomäne aus der durch Reste 28 bis 79 der SEQ ID NR. 7 dargestellten Sequenz besteht.
- 35 16. Methode zur Identifizierung einer Verbindung, die zur Modulation der Angiogenese fähig ist, wobei die Methode das Identifizieren einer Testverbindung, die an eine extrazelluläre TWEAK-Rezeptordomäne bindet, umfasst, wobei die Testverbindung nicht TWEAK ist und wobei die extrazelluläre TWEAK-Rezeptordomäne aus der durch Reste 28 bis 79 der SEQ ID NR. 7 dargestellten Sequenz besteht.
- 40 17. Methode nach Anspruch 16, wobei die Methode das Identifizieren einer Testverbindung umfasst, welche die Wechselwirkung zwischen TWEAK und einer extrazellulären TWEAK-Rezeptordomäne beeinflusst, wobei die extrazelluläre TWEAK-Rezeptordomäne aus der durch Reste 28 bis 79 der SEQ ID NR. 7 dargestellten Sequenz besteht.
- 45 18. Methode zur Identifizierung einer Verbindung, die zur Modulation der Angiogenese fähig ist, wobei die Methode das Identifizieren einer Testverbindung umfasst, welche die Angiogenese durch Modulieren der Wechselwirkung zwischen einem TWEAK-Rezeptor und TRAF moduliert, wobei der TWEAK-Rezeptor eine extrazelluläre Domäne umfasst, bestehend aus der durch Reste 28 bis 79 der SEQ ID NR. 7 dargestellten Sequenz.
- 50 19. Methode nach einem der Ansprüche 16-18, weiters umfassend das Bestimmen der Fähigkeit der Testverbindung, die Endothelzellproliferation und/oder Endothelzellmigration und/oder Angiogenese zu modulieren.
20. Methode nach einem der Ansprüche 17-19, wobei die Modulation stimulatorisch ist.
- 55 21. Methode nach einem der Ansprüche 17-19, wobei die Modulation inhibitorisch ist.

## Revendications

1. Utilisation d'un polypeptide isolé comprenant un fragment soluble du domaine extracellulaire du récepteur TWEAK qui a la capacité de se lier à TWEAK dans la production d'un médicament pour son utilisation dans l'inhibition de l'angiogenèse chez un mammifère, le domaine extracellulaire du récepteur TWEAK consistant en la séquence définie dans les résidus 28 à 79 de SEQ ID N° : 7.
2. Utilisation d'un anticorps qui se lie spécifiquement au domaine extracellulaire du récepteur TWEAK dans la production d'un médicament pour son utilisation dans la modulation de l'angiogenèse chez un mammifère, le domaine extracellulaire du récepteur TWEAK consistant en la séquence définie dans les résidus 28 à 79 de SEQ ID N° : 7.
3. Utilisation selon la revendication 1 ou 2, dans laquelle le mammifère est un être humain.
4. Utilisation selon la revendication 1, dans laquelle le polypeptide comprend un polypeptide Fc ou un domaine leucine zipper.
5. Utilisation selon la revendication 2, dans laquelle l'anticorps est choisi dans le groupe consistant en anticorps monoclonaux, anticorps humanisés, anticorps transgéniques et anticorps humains.
6. Utilisation selon la revendication 2 ou la revendication 5, dans laquelle l'anticorps est conjugué à un radio-isotope, à une toxine dérivée d'une plante, d'un champignon ou d'une bactérie telle que la ricine A ou la toxine diphtérique ou un autre poison chimique.
7. Utilisation selon la revendication 1 ou la revendication 2, dans laquelle le polypeptide ou l'anticorps rompt l'interaction entre le récepteur TWEAK et une molécule TRAF.
8. Utilisation selon l'une quelconque des revendications 1 à 7, comprenant en outre le traitement du mammifère avec un agent chimiothérapeutique.
9. Utilisation selon la revendication 8, dans laquelle l'agent chimiothérapeutique est choisi dans le groupe comprenant des agents alkylants, des antimétabolites, des alcaloïdes vinca et d'autres agents chimiothérapeutiques dérivés de plantes, des nitrosourées, des anticorps anti-tumoraux, des enzymes anti-tumorales, des inhibiteurs de la topoisomérase, des analogues du platine, des anti-cortisoliques, des hormones, des agonistes hormonaux, des antagonistes hormonaux, des anticorps, des agents immunothérapeutiques, des facteurs de cellules sanguines, des agents radiothérapeutiques et des modificateurs de la réponse biologique.
10. Utilisation selon la revendication 8, dans laquelle l'agent chimiothérapeutique est choisi dans le groupe comprenant le cisplatine, le cyclophosphalide, la méchlorétamine, le melphalan, la bléomycine, le carboplatine, le fluoro-uracile, la 5-fluorodésoxy-uridine, le méthotrexate, le taxol, l'asparaginase, la vincristine et la vinblastine, les lymphokines et les cytokines telles que les interleukines, les interférons (comprenant les interférons alpha, bêta ou delta) et le TNF, le chlorambucil, le busulfan, la carmustine, la lomustine, la sémustine, la streptozocine, la dacarbazine, la cytarabine, la mercaptopurine, la thioguanine, la vindésine, l'étoposide, le téniposide, la dactinomycine, la daunorubicine, la doxorubicine, la bléomycine, la plicamycine, la mitomycine, la L-asparaginase, les hydroxy-urées, la méthylhydrazine, le mitotane, le tamoxifène et la fluoxymestérone.
11. Utilisation selon la revendication 8, dans laquelle l'agent chimiothérapeutique est choisi dans le groupe comprenant le ligand Flt3, le ligand CD40, l'interleukine 2, l'interleukine 12, le ligand 4-1BB, les anticorps anti-4-1BB, les antagonistes du TNF et les antagonistes du récepteur du TNF, le TRAIL, les agonistes de CD148, les antagonistes du VEGF, les antagonistes du récepteur de VEGF et les antagonistes de Tek.
12. Utilisation selon la revendication 2, pour favoriser l'angiogenèse.
13. Utilisation selon la revendication 1 ou la revendication 2, pour inhiber l'angiogenèse.
14. Utilisation d'un anticorps selon l'une quelconque des revendications 2 à 13 pour :
  - (a) un traitement d'un déficit de vascularisation dans un tissu cardiaque ou périphérique comprenant une coronaropathie, une ischémie myocardique, un infarctus du myocarde, une angine de poitrine, un déficit de la

circulation périphérique, une ischémie des membres/lésion de reperfusion ;

(b) l'amélioration de la cicatrisation des plaies, de la greffe d'organe, du remplacement de doigts ou de membres sectionnés, ou d'une greffe vasculaire ou cutanée ; ou

(c) l'utilisation en association avec un pontage coronarien ou une angioplastie.

5

**15.** Antagoniste TWEAKR comprenant un polypeptide isolé comprenant un fragment soluble d'un domaine extracellulaire du récepteur TWEAK qui a la capacité de se lier à TWEAK pour son utilisation en médecine, le domaine extracellulaire du récepteur TWEAK consistant en la séquence définie dans les résidus 28 à 79 de SEQ ID N° : 7.

10 **16.** Procédé d'identification d'un composé qui est capable de moduler l'angiogenèse, le procédé comprenant l'identification d'un composé de test qui se lie à un domaine extracellulaire du récepteur TWEAK, le composé de test n'étant pas TWEAK et le domaine extracellulaire du récepteur TWEAK consistant en la séquence définie dans les résidus 28 à 79 de SEQ ID N° : 7.

15 **17.** Procédé selon la revendication 16, le procédé comprenant l'identification d'un composé de test qui affecte l'interaction entre TWEAK et un domaine extracellulaire du récepteur TWEAK, le domaine extracellulaire du récepteur TWEAK consistant en la séquence définie dans les résidus 28 à 79 de SEQ ID N° : 7.

20 **18.** Procédé d'identification d'un composé qui est capable de moduler l'angiogenèse, le procédé comprenant l'identification d'un composé de test qui module l'angiogenèse en modulant l'interaction entre un récepteur TWEAK et TRAF, le récepteur TWEAK comprenant un domaine extracellulaire consistant en la séquence définie dans les résidus 28 à 79 de SEQ ID N° : 7.

25 **19.** Procédé selon l'une des revendications 16 à 18, comprenant en outre la détermination de la capacité du composé de test à moduler la prolifération cellulaire endothéliale et/ou la migration cellulaire endothéliale et/ou l'angiogenèse.

**20.** Procédé selon l'une des revendications 17 à 19, dans lequel la modulation est stimulante.

30 **21.** Procédé selon l'une des revendications 17 à 19, dans lequel la modulation est inhibitrice.

35

40

45

50

55

```
1  MAPGWPRSLPQILVLGFGLVLMRAAAGEQAPGTSPCSSGSSWSADLDKCM 50
    || | | | .:|||| | |:|. |||||. ||||| |||||
1  MARGSLRRLRLVLGLWLALLRSVAGEQAPGTAPCSRGSWSADLDKCM 50
    . . . . .
51 DCASCPARPHSDFCLGCAAAPPAHFRLLPILGGALSLVLVLALVSSFLV 100
    ||||| ||||| ||||| ||||| ||||| |||. |||
51 DCASCRARPHSDFCLGCAAAPPAFRLLPILGGALSLTFVLGLLSGFLV 100
    . . .
101 WRRCCRREKFTTPIEETGGEGCPGVALIQ 129
    ||||| ||||| ||||| |||||
101 WRRCCRREKFTTPIEETGGEGCPAVALIQ 129
```

*Fig. 1*




Fig. 2






Fig. 3

*Fig. 4**Fig. 5*

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- WO 9835061 A, Wiley [0006] [0010]
- WO 0042073 A [0010] [0013]
- WO 9855508 A, Kato [0013] [0041] [0146]
- WO 9961471 A, Incyte [0013] [0041] [0146]
- US 5674704 A [0024]
- US 5716805 A [0027]
- US 5554512 A [0031]
- US 5447860 A, Ziegler [0037]
- WO 0075323 A, Cerretti [0037]
- US 5763223 A [0039]
- WO 9310151 A [0050]
- US 5457035 A [0050]
- US 4751180 A [0052]
- US 4935233 A [0052]
- US 5073627 A [0052]
- WO 9410308 A [0053]
- US 5814318 A [0069]
- US 5569825 A [0069]
- US 5545806 A [0069]
- EP 36776 A [0078]
- EP 73657 A, Hitzeman [0079]
- US 4965195 A [0089]
- EP 367566 A [0089]
- US 4968607 A [0089]
- EP 460846 A [0089]
- US 5843705 A [0091]
- US 5880327 A [0091]
- US 5639947 A [0091]
- US 5889189 A [0091]
- US 4109496 A, Rubenstein [0136]
- US 60172878 B [0171]
- US 60203347 B [0171]

## Non-patent literature cited in the description

- DANIEL et al. *Ann. Rev. Physiol.*, 2000, 649 [0002]
- FOLKMAN. *N. Engl. J. Med.*, 1971, vol. 285, 1182 [0004]
- FOLKMAN et al. *Nature*, 1989, vol. 339, 58 [0004]
- KIM et al. *Nature*, 1993, vol. 362, 841 [0004]
- HORI et al. *Cancer Res.*, 1991, vol. 51, 6180 [0004]
- BERGERS et al. *Science*, 1999, vol. 284, 808 [0004]
- CHICHEPORTICHE et al. *J. Biol. Chem.*, 1997, vol. 272 (51), 32401 [0006] [0144]
- SCHNEIDER et al. *Eur. J. Immunol.*, 1999, vol. 29, 1785 [0006] [0008]
- *J. Biol. Chem.*, 1999, vol. 274 (13), 8455 [0007]
- MARSTERS et al. *Current Biology*, 1998, vol. 8 (9), 525 [0008]
- MEIGHAN-MANTHA et al. *J. Biol. Chem.*, 1999, vol. 274 (46), 33166-33176 [0011]
- ASHKENAZI et al. *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 10535 [0048]
- BYRN et al. *Nature*, 1990, vol. 344, 677 [0048]
- HOLLENBAUGH ; ARUFFO. Construction of Immunoglobulin Fusion Proteins. *Current Protocols in Immunology*, 1992, vol. 4, 10.19.1-10.19.11 [0048]
- BAUM et al. *EMBO J.*, 1994, vol. 13, 3992 [0050]
- LANDSCHULZ et al. *Science*, 1988, vol. 240, 1759 [0053]
- HOPPE et al. *FEBS Lett.*, 1994, vol. 344, 191 [0053]
- FANSLOW et al. *Semin. Immunol.*, 1994, vol. 6, 267 [0053]
- NEEDLEMAN ; WUNSCH. *J. Mol. Biol.*, 1970, vol. 48, 443 [0059]
- SMITH ; WATERMAN. *Adv. Appl. Math*, 1981, vol. 2, 482 [0059]
- DEVEREUX et al. *Nucl. Acids Res.*, 1984, vol. 12, 387 [0059]
- GRIBSKOV ; BURGESS. *Nucl. Acids Res.*, 1986, vol. 14, 6745 [0059]
- Atlas of Protein Sequence and Structure. National Biomedical Research Foundation, 1979, 353-358 [0059]
- Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses. Plenum Press, 1980 [0065]
- Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1988 [0065]
- RIECHMANN et al. *Nature*, 1988, vol. 332, 323 [0067]
- LIU et al. *PNAS*, 1987, vol. 84, 3439 [0067]
- LARRICK et al. *Biol Technology*, 1989, vol. 7, 934 [0067]
- WINTER ; HARRIS. *TIPS*, May 1993, vol. 14, 139 [0067]
- SAMBROOK. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1989 [0073]
- MANIATIS. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1982 [0073]

- **AUSUBEL.** Current Protocols in Molecular Biology. Wiley and Sons, 1989 [0073]
- **POUWELS et al.** Cloning Vectors: A Laboratory Manual. Elsevier, 1985 [0075]
- **CHANG et al.** *Nature*, 1978, vol. 275, 615 [0078]
- **GOEDDEL et al.** *Nature*, 1979, vol. 281, 544 [0078]
- **GOEDDEL et al.** *Nucl. Acids Res.*, 1980, vol. 8, 4057 [0078]
- **MANIATIS.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, 1982, 412 [0078]
- **HITZEMAN et al.** *J. Biol. Chem.*, 1980, vol. 255, 2073 [0079]
- **HESS et al.** *J. Adv. Enzyme Reg.*, 1968, vol. 7, 149 [0079]
- **HOLLAND et al.** *Biochem.*, 1978, vol. 17, 4900 [0079]
- **RUSSELL et al.** *J. Biol. Chem.*, 1982, vol. 258, 2674 [0079]
- **BEIER et al.** *Nature*, 1982, vol. 300, 724 [0079]
- **KURJAN et al.** *Cell*, 1982, vol. 30, 933 [0080]
- **BITTER et al.** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 5330 [0080]
- **HINNEN et al.** *Proc. Natl. Acad. Sci. USA*, 1978, vol. 75, 1929 [0081]
- **LUCKOW ; SUMMERS.** *Bio/Technology*, 1988, vol. 6, 47 [0083]
- **GLUZMAN et al.** *Cell*, 1981, vol. 23, 175 [0084]
- **MCMAHAN et al.** *EMBO J.*, 1991, vol. 10, 2821 [0084]
- **KAUFMAN, RJ.** *Large Scale Mammalian Cell Culture*, 1990, 15-69 [0085]
- **FELGNER et al.** *Proc. Natl. Acad. Sci. USA*, 1987, vol. 84, 7413 [0085]
- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1989, vol. 1-3 [0085]
- **KAUFMAN et al.** *Meth. in Enzymology*, 1990, vol. 185, 487 [0085]
- **URLAUB ; CHASIN.** *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 4216 [0085]
- **FIERS et al.** *Nature*, 1978, vol. 273, 113 [0086]
- **KAUFMAN.** *Meth. in Enzymology*, 1990 [0086]
- **MORRIS et al.** *Animal Cell Technology*, 1997, 529-534 [0087]
- **GINGERAS et al.** *J. Biol. Chem.*, 1982, vol. 257, 13475 [0087]
- **OH ; SAMOW.** *Current Opinion in Genetics and Development*, 1993, vol. 3, 295 [0087]
- **RAMESH et al.** *Nucleic Acids Research*, 1996, vol. 24, 2697 [0087]
- **MOSSER et al.** *Biotechniques*, 1997, vol. 22, 150, 2A5I [0087]
- **MOSLEY et al.** *Cell*, 1989, vol. 59, 335 [0088]
- **OKAYAMA ; BERG.** *Mol. Cell. Biol.*, 1983, vol. 3, 280 [0088]
- **COSMAN et al.** *Mol. Immunol.*, 1986, vol. 23, 935 [0088]
- **COSMAN et al.** *Nature*, 1984, vol. 312, 768 [0088]
- **TAKAHASHI et al.** *J. Am. Soc. Nephrol.*, 1999, vol. 10, 2135-45 [0110]
- **KLEMENT et al.** *Cancer Research*, 2000, vol. 60, 1878 [0110]
- *J. Clin. Invest.*, 2000, vol. 105 (8), R15 [0110]
- **BARINAGA.** *Science*, 2000, vol. 288, 245 [0110]
- **PLATT.** *J. Biol. Chem.*, 1994, vol. 269, 28558-28562 [0114]
- **NUOVO, G. J.** PCR In Situ Hybridization: Protocols And Applications. Raven Press, 1992 [0118]
- **GIBBS.** pharmaceutical Research in Molecular Oncology. *Cell*, 1994, vol. 79 [0127]
- **MEIGHAN-MANTHA et al.** *J. Biol. Chem.*, 1999, vol. 274 (46), 33166 [0146]
- **MARSTERS et al.** *Current Biology*, 1998, vol. 8, 525 [0147]
- **KAPTEIN et al.** *FEBS Lett.*, 2000, vol. 485 (2-3), 135 [0148]
- **MARTIN et al.** *In Vitro Cell Dev Biol*, 1997, vol. 33, 261 [0156]
- **KENYON et al.** *Invest Opthamol. & Visual Science*, 1996, vol. 37, 1625 [0159]
- **GALIBERT et al.** *J. Biol. Chem.*, 1998, vol. 273 (51), 34120 [0162]



专利名称(译)	调整受体		
公开(公告)号	<a href="#">EP1239869B1</a>	公开(公告)日	2013-08-28
申请号	EP2000990269	申请日	2000-12-19
[标]申请(专利权)人(译)	株式会社Immunex公司		
申请(专利权)人(译)	株式会社Immunex公司		
当前申请(专利权)人(译)	株式会社Immunex公司		
[标]发明人	WILEY STEVEN R		
发明人	WILEY, STEVEN, R.		
IPC分类号	A61K38/17 A61K39/395 C07K14/705 C07K16/28 C12N15/12 A61P35/00 G01N33/50 A61K31/7088 A61K38/00 A61K45/00 A61K48/00 A61P9/00 A61P9/10 A61P9/14 A61P17/02 A61P37/06 C07K14/715 C12N1/15 C12N1/19 C12N1/21 C12N5/10 C12N15/09 C12P21/02 C12Q1/02 G01N33/15 G01N33/53 G01N33/566		
CPC分类号	A61K38/00 A61P17/02 C07K14/705 C07K14/70575 C07K14/70578 C07K16/2878 C07K2319/00 C07K2319/30 C07K2319/73		
优先权	60/172878 1999-12-20 US 60/203347 2000-05-10 US		
其他公开文献	EP1239869A2		
外部链接	<a href="#">Espacenet</a>		

摘要(译)	<p>tctcagagggc caccgcttta aacgtcagagg tacctatccc gggccgccac c atg gct 57 Met Ala 1</p> <p>aca ggc tcc cgg acg tcc ctg ctc ctg gct ttt ggc ctg ctc tgc ctg 105 Thr Gly Ser Arg Thr Ser Leu Leu Leu Ala Phe Gly Leu Leu Cys Leu 5 10 15</p> <p>ccc tgg ctt caa gag ggc agt gca act agt tct gac cgt atg aaa cag 153 Pro Trp Leu Gln Glu Gly Ser Ala Thr Ser Ser Asp Arg Met Lys Gln 20 25 30</p> <p>ata gag gat aag atc gaa gag atc cta agt aag att tat cat ata gag 201 Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile Glu 35 40 45 50</p> <p>aat gaa atc gcc cgt atc aaa aag ctg att ggc gag cgg act aga tct 249 Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Thr Arg Ser 55 60 65</p> <p>agt ttg ggg agc cgg gca tcg ctg tcc gcc cag gag cct gcc cag gag 297 Ser Leu Gly Ser Arg Ala Ser Leu Ser Ala Gln Glu Pro Ala Gln Glu 70 75 80</p>
-------	--

本发明提供了TWEAK受体和鉴定和使用TWEAK受体的激动剂和拮抗剂的方法。特别地，本发明提供了筛选激动剂和拮抗剂以及治疗由血管生成介导的疾病或病症的方法，例如实体瘤和心脏或外周组织的血管缺陷。